STN SEARCH TRANSCRIPT 10/645,312

"DELOMBAERT CRF ANTAGS"

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR 7):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 28  PATDPAFULL - New display fields provide for legal status
                  data from INPADOC
 NEWS  4  FEB 28  BABS - Current-awareness alerts (SDIs) available
 NEWS  5  MAR 02  GBFULL: New full-text patent database on STN
 NEWS  6  MAR 03  REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  7  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 22  KOREAPAT now updated monthly; patent information enhanced
 NEWS  9  MAR 22  Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  10 MAR 22  PATDPASPC - New patent database available
 NEWS  11 MAR 22  REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  12 APR 04  EPFULL enhanced with additional patent information and new
                  fields
 NEWS  13 APR 04  EMBASE - Database reloaded and enhanced
 NEWS  14 APR 18  New CAS Information Use Policies available online
 NEWS  15 APR 25  Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
 NEWS  16 APR 28  Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus
 NEWS  17 MAY 23  GBFULL enhanced with patent drawing images
 NEWS  18 MAY 23  REGISTRY has been enhanced with source information from
                  CHEMCATS
 NEWS  19 JUN 06  STN Patent Forums to be held in June 2005
 NEWS  20 JUN 06  The Analysis Edition of STN Express with Discover!
                  (Version 8.0 for Windows) now available
 NEWS  21 JUN 13  RUSSIAPAT: New full-text patent database on STN
 NEWS  22 JUN 13  FRFULL enhanced with patent drawing images
 NEWS  23 JUN 20  MEDICONF to be removed from STN
 NEWS  24 JUN 27  MARPAT displays enhanced with expanded G-group definitions
                  and text labels

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:42:20 ON 29 JUN 2005

=> FILE REG
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:42:30 ON 29 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 JUN 2005  HIGHEST RN 853177-57-8
DICTIONARY FILE UPDATES:  28 JUN 2005  HIGHEST RN 853177-57-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************
*                                                           *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                           *
*************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\Stnexp\Queries\DELOMBAERT CRF ANTAGs.str
```




```
chain nodes :
17  19
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12
chain bonds :
3-19  6-7  12-17
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12
exact/norm bonds :
3-19  6-7  7-8  7-12  8-9  9-10  10-11  11-12  12-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 :


G1:C,N

G2:CH,X,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-B
uO,t-BuO

G3:O,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  17:CLASS  19:CLASS



L1      STRUCTURE UPLOADED

=> que L1

L2   QUE L1

=> D L1
L1 HAS NO ANSWERS
L1                STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> S L2
SAMPLE SEARCH INITIATED 14:42:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     251 TO ITERATE

100.0% PROCESSED     251 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          4070 TO     5970
PROJECTED ANSWERS:              608 TO     1472

L3           50 SEA SSS SAM L1

=> S L2 SSS FULL
FULL SEARCH INITIATED 14:44:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    5294 TO ITERATE

100.0% PROCESSED    5294 ITERATIONS                         978 ANSWERS
SEARCH TIME: 00.00.01

L4          978 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  162.19     162.40

FILE 'CAPLUS' ENTERED AT 14:44:08 ON 29 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Jun 2005  VOL 143 ISS 1
FILE LAST UPDATED: 28 Jun 2005  (20050628/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> S L4
L5           51 L4

=> D 1-51

L5   ANSWER 1 OF 51  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2005:283493  CAPLUS
DN   142:355283
TI   Preparation of triazolopyrazines, pyrazolopyrimidines, pyrazolopyridines,
     pyrazolopyrazines and related compounds as corticotropin releasing factor
     (CRF) receptor ligands.
IN   Hodgetts, Kevin J.; John, Stanly; Moorcroft, Neil; Shutske, Greg; Kaiser,
     Bernd; Yamaguchi, Yasuchika; Ge, Ping; Horvath, Raymond F.
PA   Neurogen Corporation, USA; Aventis Pharmaceuticals Inc.
```

SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005028480	A2	20050331	WO 2004-US28663	20040903
	WO 2005028480	A3	20050602		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005070542	A1	20050331	US 2004-933700	20040903
PRAI	US 2003-500033P	P	20030903		
OS	MARPAT 142:355283				

LS ANSWER 2 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:238985 CAPLUS
DN 142:316863
TI Preparation of heteroaryl fused pyridines, pyrazines, and pyrimidines as CRF-1 receptor ligands
IN Ge, Ping; Horvath, Raymond F.; Zhang, Lu Yan; Yamaguchi, Yasuchika; Kaiser, Bernd; Zhang, Xuechun; Zhang, Suoming; Zhao, He; John, Stanly; Moorcroft, Neil; Shutske, Greg
PA Neurogen Corporation, USA; Aventis Pharmaceuticals Inc.
SO PCT Int. Appl., 290 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023806	A2	20050317	WO 2004-US28899	20040903
	WO 2005023806	A3	20050602		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005113379	A1	20050526	US 2004-933834	20040903
PRAI	US 2003-500414P	P	20030905		
OS	MARPAT 142:316863				

LS ANSWER 3 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:179880 CAPLUS
TI Palladium-Catalyzed Cross-Coupling Reactions of Pyridylboronic Acids with Heteroaryl Halides Bearing a Primary Amine Group: Synthesis of Highly Substituted Bipyridines and Pyrazinopyridines. [Erratum to document cited in CA142:198022]
AU Thompson, Amy E.; Hughes, Gregory; Batsanov, Andrei S.; Bryce, Martin R.; Parry, Paul R.; Tarbit, Brian
CS Department of Chemistry, University of Durham, Durbin, DH1 3LE, UK
SO Journal of Organic Chemistry (2005), 70(7), 2884
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal; Errata
LA English

LS ANSWER 4 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:1067792 CAPLUS
DN 142:198022
TI Palladium-Catalyzed Cross-Coupling Reactions of Pyridylboronic Acids with Heteroaryl Halides Bearing a Primary Amine Group: Synthesis of Highly Substituted Bipyridines and Pyrazinopyridines
AU Thompson, Amy E.; Hughes, Gregory; Batsanov, Andrei S.; Bryce, Martin R.; Parry, Paul R.; Tarbit, Brian
CS Department of Chemistry, University of Durham, Durham, DH1 3LE, UK
SO Journal of Organic Chemistry (2005), 70(1), 388-390
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 5 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:996174 CAPLUS
DN 141:410966
TI Preparation of pyrazineamine derivative as CRF1 receptor antagonists
IN Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Fu, Jian-Min; Hoffman, Robert L.; Verhoest, Patrick R.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099201	A1	20041118	WO 2004-IB1553	20040505
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005038040	A1	20050217	US 2004-840485	20040506
PRAI	US 2003-469486P	P	20030509		
OS	MARPAT 141:410966				
RE.CNT	4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

LS ANSWER 6 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:812360 CAPLUS
DN 141:314349
TI Preparation of libraries of compounds (e.g. pyridines, pyrazines, imidazopyrazines) capable of binding to the active site of protein kinases
IN Harris, John; Church, Nicola; Proud, Andrew; Kling, Marcel; Vickery, Benjamin D.
PA Biofocus Discovery Ltd., UK
SO Brit. UK Pat. Appl., 133 pp.
CODEN: BAXKDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2400101	A1	20041006	GB 2003-7214	20030328
	WO 2004085409	A2	20041007	WO 2004-GB1399	20040326
	WO 2004085409	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2003-7214	A	20030328		
OS	MARPAT 141:314349				
RE.CNT	9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

LS ANSWER 7 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:759828 CAPLUS
DN 141:260774
TI Preparation of pyrazinecarboxamide compounds as inhibitors of transforming growth factor (TGF) signaling pathway
IN Munchhof, Michael J.
PA Pfizer Inc., USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004180905	A1	20040916	US 2004-798198	20040310
	WO 2004080982	A1	20040923	WO 2004-IB581	20040223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-453784P	P	20030311		
OS	MARPAT 141:260774				

LS ANSWER 8 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:515493 CAPLUS
DN 141:71565
TI Preparation of pyrazines and related compounds as glucokinase activators for the treatment of type II diabetes
IN Chen, Shaoqing; Corbett, Wendy Lea; Guertin, Kevin Richard; Haynes, Nancy-Ellen; Kester, Robert Francis; Mennona, Francis A.; Mischke, Steven Gregory; Qian, Yimin; Sarabu, Ramakanth; Scott, Nathan Robert; Thakkar, Kshitij Chhabilbhai
PA F. Hoffmann-La Roche Ag, Switz.
SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052869	A1	20040624	WO 2003-EP14055	20031211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004147748	A1	20040729	US 2003-732838	20031210
PRAI	US 2002-432806P	P	20021212		
	US 2003-524531P	P	20031124		
OS	MARPAT 141:71565				

LS ANSWER 9 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182851 CAPLUS
DN 140:217663
TI Preparation of 5-substituted-2-arylpyrazines as modulators of CRF receptors
IN Yoon, Taeyoung; Ge, Ping; Delombaert, Stephane; Horvath, Raymond
PA Neurogen Corporation, USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018437	A1	20040304	WO 2003-US26141	20030820
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2496197	AA	20040304	CA 2003-2496197	20030820
	US 2004106620	A1	20040603	US 2003-645312	20030820
PRAI	US 2002-405013P	P	20020820		
	WO 2003-US26141	W	20030820		
OS	MARPAT 140:217663				
RE.CNT	2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

APPLICANTS

10/645312

LS ANSWER 10 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:60488 CAPLUS
DN 140:128431
TI Preparation of pyrazine and quinoxaline derivatives as chemokine receptor CCR4 antagonists and medicinal use thereof
IN Habashita, Hiromu; Kokubo, Masaya; Shibayama, Shiro; Tada, Hideaki;

Sagawa, Kenji
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 353 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004007472	A1	20040122	WO 2003-JP8654	20030708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1541563	A1	20050615	EP 2003-764137	20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI JP 2002-200879	A	20020710		
WO 2003-JP8654	W	20030708		

OS MARPAT 140:120431
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 11 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:20338 CAPLUS
DN 140:77031
TI N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5 receptor antagonists
IN Stamford, Andrew; Dong, Youhao; McCombie, Stuart W.; Wu, Yusheng
PA USA
SO U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S. Ser. No. 26,651.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004006086	A1	20040108	US 2002-177345	20020620
US 2003055062	A1	20030320	US 2001-26651	20011218
PRAI US 2000-257308P	P	20001221		
US 2001-26651	A2	20011218		

OS MARPAT 140:77031

LS ANSWER 12 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:892800 CAPLUS
DN 139:395950
TI Preparation of substituted pyrazines as protein kinase modulators
IN Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PA Exelixis, Inc., USA
SO PCT Int. Appl., 468 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003093297	A2	20031113	WO 2003-US13869	20030502
WO 2003093297	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2484209	AA	20031113	CA 2003-2484209	20030502
EP 1501514	A2	20050202	EP 2003-728690	20030502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-377933P	P	20020503		
WO 2003-US13869	W	20030502		

OS MARPAT 139:395950

LS ANSWER 13 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:570968 CAPLUS
DN 139:133585
TI Preparation of N-pyrazinylbenzenesulfonamides and their use in the treatment of chemokine mediated diseases such as asthma
IN Baxter, Andrew; Johnson, Timothy; Kindon, Nicholas; Roberts, Bryan; Stocks, Michael
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003059893	A1	20030724	WO 2003-SE41	20030114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472204	AA	20030724	CA 2003-2472204	20030114
EP 1467976	A1	20041020	EP 2003-700655	20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003006922	A	20041109	BR 2003-6922	20030114
PRAI SE 2002-119	A	20020116		
SE 2002-1857	A	20020617		
WO 2003-SE41	W	20030114		

OS MARPAT 139:133585
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 14 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:434540 CAPLUS
DN 139:6891
TI Preparation of substituted aryl pyrazine derivatives as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders
IN Verhoest, Patrick R.; Hoffman, Robert L.; Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Fu, Jian-Min
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 271 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003045924	A1	20030605	WO 2002-US33642	20021115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2467870	AA	20030605	CA 2002-2467870	20021115
US 2003144297	A1	20030731	US 2002-298193	20021115
EP 1446387	A1	20040818	EP 2002-780507	20021115
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
BR 2002014309	A	20041013	BR 2002-14309	20021115
US 2005049257	A1	20050303	US 2004-844004	20040512
PRAI US 2001-332052P	P	20011121		
US 2002-358546P	P	20020221		
US 2002-388285P	P	20020613		
US 2002-410378P	P	20020913		
US 2002-298193	A1	20021115		
WO 2002-US33642	W	20021115		

OS MARPAT 139:6891
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 15 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:98493 CAPLUS
DN 139:159426
TI Synthesis, structure-activity relationship and in vitro evaluation of coelenteramine and coelenteramine derivatives as inhibitors of lipid peroxidation
AU Burton, Maggi; De Tollenaere, Catherine; Cavalier, Jean-Francois; Marchand, Cecile; Dussart, Frederique; Marchand-Brynaert, Jacqueline; Rees, Jean-Francois
CS Laboratory of Cell Biology, Institut des Sciences de la Vie, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SO Free Radical Research (2003), 37(2), 145-158
CODEN: FRARER; ISSN: 1071-5762
PB Taylor & Francis Ltd.
DT Journal
LA English
OS CASREACT 139:159426
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 16 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:42253 CAPLUS
DN 138:106713
TI Preparation of heterocyclic amines for the treatment of conditions associated with GSK3
IN Berg, Stefan; Hellberg, Sven
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004475	A1	20030116	WO 2002-SE1340	20020703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1406877	A1	20040414	EP 2002-749475	20020703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004536110	T2	20041202	JP 2003-510642	20020703
US 2004186113	A1	20040923	US 2003-491699	20031222
PRAI SE 2001-2438	A	20010705		
WO 2002-SE1340	W	20020703		

OS MARPAT 138:106713
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 17 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:42250 CAPLUS
DN 138:106712
TI Preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors
IN Berg, Stefan; Hellberg, Sven
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004472	A1	20030116	WO 2002-SE1339	20020703
WO 2003004472	C1	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2452686	AA	20030116	CA 2002-2452686	20020703
EP 1414801	A1	20040506	EP 2002-747795	20020703

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

	HR 2002010838	A	20040713	BR 2002-10838	20020703
	JP 2005505515	T2	20050224	JP 2003-510640	20020703
PRAI	SE 2001-2439	A	20010705		
	WO 2002-SE1339	W	20020703		

OS MARPAT 138:106712
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:554265 CAPLUS
DN 137:243205
TI Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity
AU Cariello, Neal F.; Wilson, John D.; Britt, Ben H.; Wedd, David J.; Burlinson, Brian; Gombar, Vijay
CS Safety Assessment, GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA
SO Mutagenesis (2002), 17(4), 321-329
CODEN: MUTAEX; ISSN: 0267-8357
PB Oxford University Press
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:487401 CAPLUS
DN 137:47125
TI N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5 receptor antagonists
IN Stamford, Andrew W.; Dong, Youhao; McCombie, Stuart W.
PA Schering Corporation, USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002049648	A1	20020627	WO 2001-US49302	20011217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2432809	AA	20020627	CA 2001-2432809	20011217
	AU 2002034056	A5	20020701	AU 2002-34056	20011217
	EP 1343503	A1	20030917	EP 2001-985069	20011217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001016379	A	20030930	BR 2001-16379	20011217
	JP 2004516267	T2	20040603	JP 2002-550988	20011217
	NZ 526174	A	20041224	NZ 2001-526174	20011217
	ZA 2003004348	A	20040909	ZA 2003-4348	20030603
	NO 2003002861	A	20030821	NO 2003-2861	20030620
PRAI	US 2000-257308P	P	20001221		
	WO 2001-US49302	W	20011217		

OS MARPAT 137:47125
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:183584 CAPLUS
DN 137:41243
TI N-O glucuronidation: a major human metabolic pathway in the elimination of two novel anti-convulsant drug candidates
AU Ismail, I. M.; Dear, G. J.; Roberts, A. D.; Plumb, R. S.; Ayrton, J.; Sweatman, B. C.; Bowers, G. D.
CS Structural Identification Group, GlaxoSmithKline Research and Development, Ware, SG12 0DP, UK
SO Xenobiotica (2002), 32(1), 29-43
CODEN: XENOBH; ISSN: 0049-8254
PB Taylor & Francis Ltd.
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:10467 CAPLUS
DN 136:69823
TI Preparation of imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
IN Konno, Fujiko; Nagao, Yoshihiro; Isomae, Kazuo; Ohtsuka, Mari; Takahashi, Yoshiyuki; Ishii, Fumio; Hirota, Hiroyuki; Takeda, Sunao; Kawamoto, Noriyuki; Honda, Haruyoshi; Sato, Susumu
PA Ssp Co., Ltd., Japan
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000648	A1	20020103	WO 2001-JP4836	20010608
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001064223	A5	20020108	AU 2001-64223	20010608
	CA 2410391	AA	20021128	CA 2001-2410391	20010608
	EP 1295880	A1	20030326	EP 2001-938563	20010608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003207896	A1	20031106	US 2002-258610	20021105
PRAI	JP 2000-194024	A	20000628		
	WO 2001-JP4836	W	20010608		

OS MARPAT 136:69823
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:10260 CAPLUS
DN 136:74644
TI Novel process for preparing and harvesting crystalline pharmaceutical particles
IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000199	A1	20020103	WO 2001-GB2923	20010629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1294360	A1	20030326	EP 2001-943685	20010629
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004500984	T2	20040115	JP 2002-504981	20010629
	US 2004045805	A1	20040311	US 2003-312434	20030606
PRAI	GB 2000-16040	A	20000629		
	WO 2001-GB2923	W	20010629		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:10259 CAPLUS
DN 136:74643
TI Process for preparing and harvesting crystalline pharmaceutical particles
IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000198	A1	20020103	WO 2001-GB2922	20010629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1294359	A1	20030326	EP 2001-943684	20010629
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004500983	T2	20040115	JP 2002-504980	20010629
	US 2003181432	A1	20030925	US 2003-312423	20030529
PRAI	GB 2000-15981	A	20000629		
	WO 2001-GB2922	W	20010629		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:859509 CAPLUS
DN 136:270314
TI Fluorescence properties of phenolate anions of coelenteramide analogues: the light-emitter structure in aequorin bioluminescence
AU Imai, Yuko; Shibata, Takuya; Maki, Shojiro; Niwa, Haruki; Ohashi, Mamoru; Hirano, Takashi
CS Department of Applied Physics and Chemistry, The University of Electro-Communications, Chofu, Tokyo, 182-8585, Japan
SO Journal of Photochemistry and Photobiology, A: Chemistry (2001), 146(1-2), 95-107
CODEN: JPPCEJ; ISSN: 1010-6030
PB Elsevier Science S.A.
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:833264 CAPLUS
DN 135:357945
TI Two-step process for the preparation of 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine
IN Edney, Dean David; Kennedy, Andrew
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085674	A1	20011115	WO 2001-GB1929	20010502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1278721	A1	20030129	EP 2001-925711	20010502
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003532702	T2	20031105	JP 2001-582275	20010502
	US 2003149053	A1	20030807	US 2002-275457	20021105
	US 6803464	B2	20041012		
PRAI	GB 2000-10971	A	20000505		
	WO 2001-GB1929	W	20010502		

OS CASREACT 135:357945
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:617986 CAPLUS
DN 135:180787
TI Preparation of substituted arylpyrazines and their binding with CRF1 receptors
IN Yoon, Taeyoung; Ge, Ping; Horvath, Raymond F.; De Lombaert, Stephane; Hodgetts, Kevin J.; Doller, Dario; Zhang, Cunyu
PA Neurogen Corporation, USA
SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060806	A2	20010823	WO 2001-US5264	20010216
	WO 2001060806	A3	20020207		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2398937	AA	20010823	CA 2001-2398937	20010216
	EP 1255740	A2	20021113	EP 2001-910939	20010216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003018035	A1	20030123	US 2001-788315	20010216
	EE 200200453	A	20031215	EE 2002-453	20010216
	JP 2004500383	T2	20040108	JP 2001-560191	20010216
	BR 2001008363	A	20040210	BR 2001-8363	20010216
	EP 1500653	A1	20050126	EP 2004-25531	20010216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 520484	A	20050324	NZ 2001-520484	20010216
	BG 106968	A	20030430	BG 2002-106968	20020731
	ZA 2002006103	A	20030820	ZA 2002-6103	20020731
	NO 2002003869	A	20020911	NO 2002-3869	20020815
PRAI	US 2000-182934P	P	20000216		
	US 2000-206455P	P	20000522		
	EP 2001-910939	A3	20010216		
	WO 2001-US5264	W	20010216		
OS	MARPAT 135:180787				

LS ANSWER 27 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:472472 CAPLUS
DN 135:81972
TI Formulations of adenosine A1 agonists
IN Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001045684	A2	20010628	WO 2000-GB4888	20001219
	WO 2001045684	A3	20020314		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1239880	A2	20020918	EP 2000-985631	20001219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003518042	T2	20030603	JP 2001-546423	20001219
	US 2003008842	A1	20030109	US 2002-168196	20020618
PRAI	GB 1999-30079	A	19991220		
	WO 2000-GB4888	W	20001219		

LS ANSWER 28 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:314448 CAPLUS
DN 135:118864
TI Catechol derivatives of aminopyrazine and cell protection against uvb-induced mortality
AU Cavalier, J.-F.; Burton, M.; Dussart, F.; Marchand, C.; Rees, J.-F.; Marchand-Brynaert, J.
CS Unite de Chimie Organique et Medicinale, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SO Bioorganic & Medicinal Chemistry (2001), 9(4), 1037-1044
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 29 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:78356 CAPLUS
DN 134:131548
TI Preparation of tricyclic compounds as allergy inhibitors, immunosuppressants, and IgE production inhibitors
IN Tanimoto, Norihiko; Inagaki, Masanao
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007401	A1	20010201	WO 2000-JP4726	20000714
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000060160	A5	20010213	AU 2000-60160	20000714
PRAI	JP 1999-209298	A	19990723		
	JP 1999-211702	A	19990727		
	WO 2000-JP4726	W	20000714		
OS	MARPAT 134:131548				
RE.CNT	9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

LS ANSWER 30 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:456951 CAPLUS
DN 133:79433
TI Apparatus and process for preparing crystalline particles
IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2000038811	A1	20000706	WO 1999-GB4368	19991222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6482438	B1	20021119	US 1999-348948	19990707
	CA 2356897	AA	20000706	CA 1999-2356897	19991222
	BR 9916587	A	20010925	BR 1999-16587	19991222
	EP 1144065	A1	20011017	EP 1999-962413	19991222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	TR 200101845	T2	20011022	TR 2001-200101845	19991222
	JP 2002533205	T2	20021008	JP 2000-590755	19991222
	JP 3588050	B2	20041110		
	NZ 512400	A	20030228	NZ 1999-512400	19991222
	AU 759880	B2	20030501	AU 2000-18771	19991222
	NO 2001003039	A	20010822	NO 2001-3039	20010619
	ZA 2001005070	A	20020920	ZA 2001-5070	20010620
PRAI	GB 1998-28721	A	19981224		
	WO 1999-GB4368	W	19991222		
RE.CNT	4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

LS ANSWER 31 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:335409 CAPLUS
DN 132:334474
TI Preparation of spiroindolines as 5HT receptor antagonists
IN Gao, Ying-duo; Macneil, Douglas J.; Yang, Lihu; Morin, Nancy R.; Fukami, Takehiro; Kanatani, Akio; Fukuroda, Takahiro; Ishii, Yasuyuki; Morin, Masaki
PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.; et al.
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027845	A1	20000518	WO 1999-US26447	19991108
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2350714	AA	20000518	CA 1999-2350714	19991108
	US 6191160	B1	20010220	US 1999-436120	19991108
	EP 1129089	A1	20010905	EP 1999-971808	19991108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 756797	B2	20030123	AU 2000-14732	19991108
	US 6313298	B1	20011106	US 2000-656698	20000907
	US 2002058813	A1	20020516	US 2001-896940	20010629
	US 6495559	B2	20021217		
	US 6638942	B1	20031028	US 2002-228250	20020826
	US 2004063942	A1	20040401	US 2003-624414	20030721
PRAI	US 1998-107835P	P	19981110		
	US 1999-436120	A3	19991108		
	WO 1999-US26447	W	19991108		
	US 2000-656698	A3	20000907		
	US 2001-896940	A3	20010629		
	US 2002-228250	A3	20020826		
OS	MARPAT 132:334474				
RE.CNT	1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

LS ANSWER 32 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:161266 CAPLUS
DN 132:194395
TI Preparation of pyrazines as anticonvulsants
IN Cox, Brian; Healy, Mark Patrick; Wild, Deborah
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012488	A1	20000309	WO 1999-EP6248	19990826
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2341543	AA	20000309	CA 1999-2341543	19990826
	AU 9956249	A1	20000321	AU 1999-56249	19990826
	BR 9913183	A	20010515	BR 1999-13183	19990826
	EP 1107960	A1	20010620	EP 1999-942919	19990826
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100603	T2	20010723	TR 2001-200100603	19990826
	JP 2002523499	T2	20020730	JP 2000-567518	19990826
	TW 429255	B	20010411	TW 1999-88114723	19990827
	US 6503909	B1	20030107	US 2001-762295	20010208
	US 2003022904	A1	20030130	US 2002-216399	20020812
PRAI	GB 1998-18881	A	19980828		
	WO 1999-EP6248	W	19990826		
	US 2001-762295	A1	20010208		
OS	MARPAT 132:194395				
RE.CNT	1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

LS ANSWER 33 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:495258 CAPLUS
DN 131:129907
TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors
IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiro
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9938829	A1	19990805	WO 1999-JP297	19990126
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2318368	AA	19990805	CA 1999-2318368	19990126
	AU 9919837	A1	19990816	AU 1999-19837	19990126
	AU 742641	B2	20020110		
	EP 1052238	A1	20001115	EP 1999-900676	19990126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9908539	A	20001205	BR 1999-8539	19990126
	TR 200002225	T2	20001221	TR 2000-200002225	19990126
	NZ 506101	A	20030630	NZ 1999-506101	19990126
	RU 2216533	C2	20031120	RU 2000-121556	19990126
	NO 2000003706	A	20000914	NO 2000-3706	20000719
	US 6562817	B1	20030513	US 2000-600790	20000721
PRAI	JP 1998-15554	A	19980128		
	WO 1999-JP297	W	19990126		

OS MARPAT 131:129907
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 34 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:608606 CAPLUS
DN 129:230741
TI Preparation of pyrazines as anticonvulsants
IN Cox, Brian; Nobbs, Malcolm Stuart; Shah, Gita Punjabhai; Edney, Dean David; Loft, Michael Simon
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 45 pp.
CODEN: PIXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9838174	A1	19980903	WO 1998-EP1077	19980226
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2282585	AA	19980903	CA 1998-2282585	19980226
	AU 9860237	A1	19980918	AU 1998-60237	19980226
	AU 732915	B2	20010503		
	ZA 9801624	A	19990826	ZA 1998-1624	19980226
	EP 966448	A1	19991229	EP 1998-913592	19980226
	EP 966448	B1	20031001		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9807814	A	20000222	BR 1998-7814	19980226
	EE 9900376	A	20000417	EE 1999-376	19980226
	TR 9902082	T2	20000421	TR 1999-9902082	19980226
	JP 2000511203	T2	20000829	JP 1998-537310	19980226
	JP 3369189	B2	20030120		
	NZ 337121	A	20010330	NZ 1998-337121	19980226
	JP 2002308773	A2	20021023	JP 2002-47974	19980226
	CN 1105111	B	20030409	CN 1998-804593	19980226
	IL 131293	A1	20030731	IL 1998-131293	19980226
	AT 251143	E	20031015	AT 1998-913592	19980226
	PT 966448	T	20040227	PT 1998-913592	19980226
	ES 2205469	T3	20040501	ES 1998-913592	19980226
	TW 513416	B	20021211	TW 1998-87103079	19980303
	US 6255307	B1	20010703	US 1999-380062	19990825
	MX 9907910	A	20000228	MX 1999-7910	19990826
	NO 9904213	A	19991029	NO 1999-4213	19990831
	NO 313383	B1	20020923		
	BG 103723	A	20010531	BG 1999-103723	19990909
	HK 1023116	A1	20040116	HK 2000-102173	20000410
	US 2002169172	A1	20021114	US 2001-855703	20010516
	US 6599905	B2	20030729		
PRAI	GB 1997-4275	A	19970301		
	GB 1997-8103	A	19970423		
	JP 1998-537310	A3	19980226		
	WO 1998-EP1077	W	19980226		
	US 1999-380062	A3	19990825		

OS MARPAT 129:230741
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 35 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:482779 CAPLUS
DN 129:227130
TI Bioluminescent properties of fluorinated semi-synthetic aequorins
AU Hirano, Takashi; Ohmiya, Yoshihiro; Maki, Shojiro; Niwa, Haruki; Ohashi, Mamoru
CS Department of Applied Physics and Chemistry, The University of Electro-Communications, Tokyo, 182, Japan
SO Tetrahedron Letters (1998), 39(31), 5541-5544
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 36 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:613880 CAPLUS
DN 127:293247
TI Preparation of pyrrolopyrazines as GABAa receptor ligands
IN Blum, Charles; Hutchison, Alan
PA Neurogen Corp., USA
SO U.S., 16 pp., Cont.-in-part of U.S. 5,606,059.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5668283	A	19970916	US 1995-486595	19950607
	US 5286860	A	19940215	US 1992-975409	19921112
	US 5606059	A	19970225	US 1995-436252	19950512
	US 5910590	A	19990608	US 1997-931648	19970916
PRAI	US 1992-975409	A2	19921112		
	US 1995-436252	A2	19950512		
	WO 1993-US10870	W	19931110		
	US 1995-486595	A1	19950607		

OS MARPAT 127:293247

LS ANSWER 37 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:99369 CAPLUS
DN 124:146199
TI Preparation of 2,3-dicyanobenzofuro[2,3-b]pyrazine derivatives as fluorescent substances
IN Matsuoka, Masaru; Matsushima, Yoshimasa
PA Takasago Perfumery Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07247288	A2	19950926	JP 1994-65424	19940310
PRAI	JP 1994-65424		19940310		

OS CASREACT 124:146199; MARPAT 124:146199

LS ANSWER 38 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:541426 CAPLUS
DN 122:290892
TI Preparation of diphenylpyrazine derivatives as herbicides
IN Yanai, Toshiaki; Tsukamoto, Yoshihisa; Sakamoto, Takashi; Teramura, Masahiro; Pponma, Toyokuni
PA Sankyo Co, Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07033752	A2	19950203	JP 1993-176525	19930716
PRAI	JP 1993-176525		19930716		

OS MARPAT 122:290892

LS ANSWER 39 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:508837 CAPLUS
DN 121:108837
TI Liquid crystalline di-, tri- and tetrafluorophenylpyrazines
IN Brown, John William; Hurst, Derek Thomas; O'Donovan, Jacqueline Patricia; Coates, David; Greenfield, Simon; Goulding, Mark John; Gray, George William
PA Merck Patent GmbH, Germany
SO Brit. UK Pat. Appl., 22 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2272216	A1	19940511	GB 1992-23244	19921104
PRAI	GB 1992-23244		19921104		

OS MARPAT 121:108837

LS ANSWER 40 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:483377 CAPLUS
DN 121:83377
TI (Biphenylyl)pyrazines for liquid crystalline media
IN Brown, John William; Hurst, Derek Thomas; O'Donovan, Jacqueline Patricia; Coates, David; Greenfield, Simon; Goulding, Mark John; Gray, George William
PA Merck Patent GmbH, Germany
SO Brit. UK Pat. Appl., 40 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2271351	A1	19940413	GB 1992-21139	19921008
PRAI	GB 1992-21139		19921008		

OS MARPAT 121:83377

LS ANSWER 41 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:269942 CAPLUS
DN 120:269942
TI Preparation of Cypridinida's luciferin derivatives as luminescent probes for chemiluminescence immunoassay
IN Sawada, Hideo; Totani, Yoshiaki; Mitani, Motohiro; Ichikawa, Hideji; Matsumoto, Takeo
PA Nippon Oils & Fats Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05286976	A2	19931102	JP 1992-13167	19920128
	JP 3314397	B2	20020812		
PRAI	JP 1992-13167		19920128		

OS MARPAT 120:269942

LS ANSWER 42 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:245160 CAPLUS
DN 120:245160
TI Preparation of indolopyrazines and related compounds as brain GABAa agonists, antagonists, or inverse agonists
IN Blum, Charles; Hutchison, Alan
PA Neurogen Corp., USA
SO U.S., 17 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5286860	A	19940215	US 1992-975409	19921112
	WO 9411374	A1	19940526	WO 1993-US10870	19931110
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9455526	A1	19940608	AU 1994-55526	19931110
	US 5606059	A	19970225	US 1995-436252	19950512
	US 5668283	A	19970916	US 1995-486595	19950607
PRAI	US 1992-975409	A	19921112		
	WO 1993-US10870	W	19931110		
	US 1995-436252	A2	19950512		

OS MARPAT 120:245160

LS ANSWER 43 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1992:571380 CAPLUS
DN 117:171380
TI Metalation of diazines. VI. Metalation of pivaloylaminopyrazine and N-tert-butylpyrazinamide. Unusual regioselectivity in the metalation

reaction.
AU Turck, A.; Ple, N.; Trohay, D.; Ndzi, B.; Queguiner, G.
CS Lab. Chim. Org. Fine Heterocyclique, INSA, Mt. St. Aignan, 76131, Fr.
SO Journal of Heterocyclic Chemistry (1992), 29(4), 699-702
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 117:171380

LS ANSWER 44 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1982:35307 CAPLUS
DN 96:35307
TI 1-(Mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
IN Miesel, John L.
PA Eli Lilly and Co., USA
SO U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 881,300, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4293552	A	19811006	US 1979-62393	19790731
PRAI US 1978-881300	A2	19780227		

LS ANSWER 45 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1980:620777 CAPLUS
DN 93:220777
TI Substituted 2-aminopyrazines
IN Barnett, Charles J.; Ennick, Thomas L.; Hoying, Richard C.
PA Eli Lilly and Co., USA
SO U.S., 11 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4211870	A	19800708	US 1979-27630	19790406
DK 8001442	A	19801007	DK 1980-1442	19800402
FI 8001056	A	19801007	FI 1980-1056	19800402
AU 8057102	A1	19801009	AU 1980-57102	19800402
FR 2453159	A1	19801031	FR 1980-7457	19800402
BR 8002079	A	19801125	BR 1980-2079	19800402
ES 490287	A1	19810516	ES 1980-490287	19800402
CS 215055	P	19820730	CS 1980-2293	19800402
CA 1157860	A1	19831129	CA 1980-349061	19800402
BE 882608	A1	19801003	BE 1980-9771	19800403
EP 18144	A1	19801029	EP 1980-301085	19800403
R: DE, GB, NL, SE				
GB 2046751	A	19801119	GB 1980-11363	19800403
GB 2046751	A1	19801119		
DD 150057	C	19810812	DD 1980-220207	19800403
ZA 8002005	A	19811125	ZA 1980-2005	19800403
HU 26151	O	19830928	HU 1980-817	19800403
SU 932989	A3	19820530	SU 1980-2902455	19800404
RO 79384	P	19820625	RO 1980-100722	19800404
JP 55141473	A2	19801105	JP 1980-45114	19800405
PRAI US 1979-27630	A	19790406		

LS ANSWER 46 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1979:540598 CAPLUS
DN 91:140598
TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
IN Miesel, John L.
PA Eli Lilly and Co., USA
SO U.S., 19 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4160834	A	19790710	US 1977-861733	19771219
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
PRAI US 1974-507492	A2	19740919		
US 1975-595904	A2	19750714		
US 1977-775813	A2	19770309		
AT 1975-7146	A	19750917		

LS ANSWER 47 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1979:152238 CAPLUS
DN 90:152238
TI 1-(Mono-o-substituted benzoyl)-3-(substituted pyrazinyl)ureas
IN Miesel, John Louis; Abdulla, Riaz Fazal; Terando, Norman Henry
PA Eli Lilly and Co., USA
SO Ger. Offen., 86 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2826893	A1	19790118	DE 1978-2826893	19780619
US 4133956	A	19790109	US 1977-819639	19770727
IL 54928	A1	19820228	IL 1978-54928	19780615
IL 64263	A1	19820930	IL 1978-64263	19780615
FR 2398738	A1	19790223	FR 1978-18187	19780616
FR 2398738	B1	19810508		
IN 149912	A	19820529	IN 1978-CA666	19780616
BR 868220	A1	19781219	BE 1978-8936	19780619
GB 2001053	A	19790124	GB 1978-27260	19780619
GB 2001053	B2	19820526		
AU 516505	B2	19810604	AU 1978-37249	19780619
AU 7837249	A1	19800103		
GB 2066806	A	19810715	GB 1980-19107	19780619
GB 2066806	B2	19820818		
AT 7804456	A	19811015	AT 1978-4456	19780619
AT 367046	B	19820525		
CA 1129861	A1	19820817	CA 1978-305703	19780619
HU 23227	O	19820830	HU 1978-EI793	19780620
HU 180726	B	19830429		
RO 78069	P	19830803	RO 1978-94410	19780620
HU 29287	O	19840130	HU 1982-1470	19780620
HU 185336	B	19850128		
DK 7802793	A	19781223	DK 1978-2793	19780621
SE 7807127	A	19781223	SE 1978-7127	19780621
NL 7806678	A	19781220	NL 1978-6678	19780621
BR 7803939	A	19790220	BR 1978-3939	19780621
ZA 7803553	A	19800227	ZA 1978-3553	19780621
CS 198104	P	19800530	CS 1978-4095	19780621
CS 198105	P	19800530	CS 1978-8519	19780621
CS 198106	P	19800530	CS 1978-8520	19780621
SU 799662	D	19810123	SU 1978-2628947	19780621
CH 638500	A	19830930	CH 1978-6770	19780621
JP 54009288	A2	19790124	JP 1978-76343	19780622
ES 471057	A1	19800116	ES 1978-471057	19780622
DD 141831	C	19800521	DD 1978-206203	19780622
DD 143721	C	19800910	DD 1978-213690	19780622
PL 115711	B1	19810430	PL 1978-207831	19780622
ES 471879	A1	19790201	ES 1978-471879	19780719
CA 1103251	A1	19810616	CA 1978-308083	19780725
FR 2398739	A1	19790223	FR 1978-32550	19781117
FR 2398739	B1	19821105		
IL 64216	A1	19821231	IL 1979-64216	19790615
AT 8101716	A	19820415	AT 1981-1716	19810415
DK 8103054	A	19810709	DK 1981-3054	19810709
SE 8303206	A	19830607	SE 1983-3206	19830607
PRAI GB 1977-26093	A	19770622		
US 1977-819639	A	19770727		
IL 1978-54928	A3	19780615		
AT 1978-4456	A	19780619		
GB 1978-27260	A	19780619		
DK 1978-2793	A	19780621		

LS ANSWER 48 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1978:509584 CAPLUS
DN 89:109584
TI Insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas
IN Miesel, John Louis
PA Eli Lilly and Co., USA
SO U.S., 15 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4083977	A	19780411	US 1976-742948	19761118
US 3984137	A	19761005	US 1975-595504	19750714
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
PRAI US 1974-507492	A2	19740919		
US 1975-595504	A3	19750714		
AT 1975-7146	A	19750917		

LS ANSWER 49 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1978:50924 CAPLUS
DN 88:50924
TI 1-Benzoyl-3-pyrazinylureas
PA Eli Lilly and Co., USA
SO Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 52010285	A2	19770126	JP 1976-1426	19760101
PRAI US 1975-595904	A	19750714		

LS ANSWER 50 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1976:421468 CAPLUS
DN 85:21468
TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
IN Miesel, John L.
PA Eli Lilly and Co., USA
SO Ger. Offen., 70 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2541116	A1	19760408	DE 1975-2541116	19750915
DE 2541116	C2	19850718		
IN 142286	A	19770618	IN 1975-CA1744	19750910
BE 833288	A1	19760311	BE 1975-1006877	19750911
IL 48092	A1	19790312	IL 1975-48092	19750912
AU 7584845	A1	19770324	AU 1975-84845	19750915
GB 1521714	A	19780816	GB 1975-37933	19750916
CA 1070308	A1	19800122	CA 1975-235561	19750916
NL 7510901	A	19760323	NL 1975-10901	19750917
ZA 7505945	A	19770427	ZA 1975-5945	19750917
AT 7507146	A	19771015	AT 1975-7146	19750917
CS 195710	P	19800229	CS 1975-6298	19750917
DK 7504195	A	19760320	DK 1975-4195	19750918
SE 7510474	A	19760322	SE 1975-10474	19750918
SE 426066	B	19821206		
SE 426066	C	19830317		
PL 102954	P	19790531	PL 1975-197527	19750918
PL 106054	P	19791130	PL 1975-183470	19750918
CH 617192	A	19800514	CH 1975-12147	19750918
HU 19446	O	19810228	HU 1975-EI646	19750918
HU 177200	P	19810828		
JP 51056480	A2	19760518	JP 1975-114226	19750919
BR 7506073	A	19760803	BR 1975-6073	19750919
FR 2299327	A1	19760827	FR 1975-28772	19750919
FR 2299327	B1	19780407		
DD 123341	C	19761212	DD 1975-188451	19750919
ES 441124	A1	19770616	ES 1975-441124	19750919
DD 128762	C	19771207	DD 1975-196898	19750919
SU 662011	D	19790505	SU 1975-2171811	19750919
SU 660566	D	19790430	SU 1976-2380308	19760709
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
SE 7806517	A	19780602	SE 1978-6517	19780602
SE 420042	B	19810914		
SE 420042	C	19820107		
PRAI US 1974-507492	A	19740919		
AT 1975-7146	A	19750917		

LS ANSWER 51 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1973:537092 CAPLUS
DN 79:137092
TI Pteridines. XXIX. Unequivocal route to 2,4-diamino-6-substituted pteridines
AU Taylor, Edward C.; Perlman, Katherine L.; Kim, Young-Ho; Sword, Ian P.; Jacobi, Peter A.
CS Dep. Chem., Princeton Univ., Princeton, NJ, USA
SO Journal of the American Chemical Society (1973), 95(19), 6413-18
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English

=> LOG HOLD
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	56.55	218.95

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:44:37 ON 29 JUN 2005

Connecting via Winsock to STN

ONLY PRIOR ART HITS FROM L5 SELECTED — THOSE RECORDS ARE DISPLAYED IBIB, ABS, HIT STR . . .

```
Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 14:51:17 ON 29 JUN 2005
FILE 'CAPLUS' ENTERED AT 14:51:17 ON 29 JUN 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                        SINCE FILE     TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                           56.55     218.95

=> D HIS

     (FILE 'HOME' ENTERED AT 14:42:20 ON 29 JUN 2005)

     FILE 'REGISTRY' ENTERED AT 14:42:30 ON 29 JUN 2005
L1             STRUCTURE UPLOADED
L2             QUE L1
L3          50 S L2
L4         978 S L2 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:44:08 ON 29 JUN 2005
L5          51 S L4

=> D L5 11, 12, 14, 18-51 IBIB ABS HITSTR

L5   ANSWER 11 OF 51  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:20338  CAPLUS
DOCUMENT NUMBER:          140:77031
TITLE:                    N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5
                          receptor antagonists
INVENTOR(S):              Stamford, Andrew; Dong, Youhao; McCombie, Stuart W.;
                          Wu, Yusheng
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S.
                          Ser. No. 26,651.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    ---------------------  --------
     US 2004006086        A1    20040108    US 2002-177345         20020620
     US 2003055062        A1    20030320    US 2001-26651          20011218
PRIORITY APPLN. INFO.:                      US 2000-257308P     P  20001221
                                            US 2001-26651       A2 20011218

OTHER SOURCE(S):          MARPAT 140:77031
GI
```



II

```
AB   RZNHCONMeZ1R1 [I; R = fluorophenyl; R1 = alkanoyl, alkylsulfonyl,
     pyridinylcarbonyl], etc.; Z = pyridine-, pyrazine-, or
     pyrimidine-2,5-diyl, etc.; Z1 = e.g., piperidine-4,1-diyl] were prepared
     Thus, 3,5-F2C6H3B(OH)2 was condensed with 2-bromo-5-nitropyridine and the
     reduced product condensed with COCl2 and N-methyl-1-(2-
     pyridinyl)piperidine-4-amine to give II.  Data for biol. activity of I
     were given.  Pharmaceutical composition comprising the compound I is claimed.
IT   438584-80-6P 438584-81-7P 438584-82-8P
     438584-83-9P 438584-84-0P 438584-96-4P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5
        receptor antagonists)
RN   438584-80-6  CAPLUS
CN   4-Piperidinamine, 1-acetyl-N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carb
     onyl]-N-methyl- (9CI)  (CA INDEX NAME)
```



```
RN   438584-81-7  CAPLUS
CN   4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-
     methyl-1-(1-oxopropyl)- (9CI)  (CA INDEX NAME)
```



```
RN   438584-82-8  CAPLUS
CN   4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-
     methyl-1-(2-methyl-1-oxopropyl)- (9CI)  (CA INDEX NAME)
```



```
RN   438584-83-9  CAPLUS
CN   4-Piperidinamine, 1-(cyclopropylcarbonyl)-N-[[[5-(2,5-
     difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI)  (CA INDEX NAME)
```



```
RN   438584-84-0  CAPLUS
CN   4-Piperidinamine, 1-(cyclopentylcarbonyl)-N-[[[5-(2,5-
     difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI)  (CA INDEX NAME)
```



```
RN   438584-96-4  CAPLUS
CN   4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-
     methyl-1-(methylsulfonyl)- (9CI)  (CA INDEX NAME)
```



```
L5   ANSWER 12 OF 51  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2003:892800  CAPLUS
DOCUMENT NUMBER:          139:395950
TITLE:                    Preparation of substituted pyrazines as protein kinase
                          modulators
INVENTOR(S):              Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai,
                          Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn,
                          Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko,
                          Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John
                          M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed
                          Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy,
                          James William; Chen, Jeff; Dalrymple, Lisa Esther;
                          Forsyth, Thimothy Patrick; Huynh, Tai Phat; Mann,
                          Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PATENT ASSIGNEE(S):       Exelixis, Inc., USA
SOURCE:                   PCT Int. Appl., 468 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    ---------------------  --------
     WO 2003093297        A2    20031113    WO 2003-US13869        20030502
     WO 2003093297        A3    20040701
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2484209           AA    20031113    CA 2003-2484209        20030502
     EP 1501514           A2    20050202    EP 2003-728690         20030502
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.:                      US 2002-377933P     P  20020503
                                            WO 2003-US13869     W  20030502

OTHER SOURCE(S):          MARPAT 139:395950
GI
```



I

```
AB   This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H,
     alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS,
     C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 =
     (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.;
     R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7
     membered heteroalicyclyl; W = 6-10 membered arylene, 5-10 membered
     heteroarylene; Y = a bond, (un)substituted alkylene, O(CH2)2-30, etc.; Y =
     H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic
     activity for modulating cellular activities such as proliferation,
     differentiation, programmed cell death, migration and chemoinvasion, and
     to pharmaceutical compns. containing such compds.  Even more specifically, the
     invention relates to compds. I that inhibit, regulate and/or modulate
     kinases, particularly Checkpoint Kinases, even more particularly
     Checkpoint Kinase 1, or Chk1.  Preparation of representative compds. I is
```

described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

IT 625459-31-6P 625459-40-7P 625459-42-9P
625459-44-1P 625463-13-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of protein kinase modulators)

RN 625459-31-6 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 625459-40-7 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 625459-42-9 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 625459-44-1 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 625463-13-0 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[2-fluoro-5-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



LS ANSWER 14 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:434540 CAPLUS
DOCUMENT NUMBER: 139:6891
TITLE: Preparation of substituted aryl pyrazine derivatives as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders
INVENTOR(S): Verhoest, Patrick R.; Hoffman, Robert L.; Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Fu, Jian-Min
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 271 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045924	A1	20030605	WO 2002-US33642	20021115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2467870	AA	20030605	CA 2002-2467870	20021115
US 2003144297	A1	20030731	US 2002-298193	20021115
EP 1446387	A1	20040818	EP 2002-780507	20021115
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
BR 2002014309	A	20041013	BR 2002-14309	20021115
US 2005049257	A1	20050303	US 2004-844004	20040512
PRIORITY APPLN. INFO.:			US 2001-332052P	P 20011121
			US 2002-358546P	P 20020221
			US 2002-388285P	P 20020613
			US 2002-410378P	P 20020913
			US 2002-298193	A1 20021115
			WO 2002-US33642	W 20021115

OTHER SOURCE(S): MARPAT 139:6891
GI



AB Substituted aryl 1,4-pyrazine derivs. (shown as I; variables defined below; e.g. 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine) and their use in treating anxiety disorders, depression and stress related disorders are disclosed. The binding affinity of I for the corticotropin releasing factor type I receptor expressed as IC50 values generally ranges from .apprx.0.5 nM to .apprx.10 μM; no specific values are given. Although the methods of preparation are not claimed, 131 example prepns. of I and 190 example prepns. of intermediates are included. For I: X = -NR3R4, -OR3, -CR3R5R5, -C(O)R3, -S(O)mR3, - NR3C(O)R4, or -NR3S(O)mR4, m = 0-2; Ar = aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R1, R2, and R5 = halogen, -NO2, -CN, -Ra, -ORa, -S(O)mRa, -NRaRa, -C(O)NRaRa, -C(S)NRaRa, -S(O)mNRaRa, -NRaS(O)mRa, -NRaC(O)ORa, -OC(O)NRaRa, -NRaC(O)NRaRa, -NRaC(S)NRaRa, -C(O)ORa, -C(S)ORa, or -OC(O)ORa. R3 and R4 = Ra or substituted and/or unsubstituted heterocycloalkyl, heteroaryl, aryl, aryl cycloalkyl, heteroaryl cycloalkyl, aryl heterocycloalkyl, or heteroaryl heterocycloalkyl; Ra = H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl (un)substituted with 1 to 5 of Rt, -ORt, -S(O)mRt, NRtRt, oxo, thione (:S), Ph, heteroaryl, or heterocycloalkyl; Rt = H, halogen, -NO2, -NH2, -OH, -SH, -CN, -C(O)NH2, - C(O)NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)malkyl, SO2NH2, SO2NHalkyl and SO2Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, Ph, benzyl, heteroaryl, or heterocycloalkyl; addnl. details including specifically excluded compds. are given in the claims. Compds. I are also claimed effective for screening ligands for CRF1 receptors and for detecting CRF1 receptors in tissues.

IT 535936-71-1P, cis-5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-(4-propoxytetrahydrofuran-3-yl)pyrazin-2-amine
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate and receptor detection and ligand screening agent, chromatog. resolution; preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535936-71-1 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-tetrahydro-4-propoxy-3-furanyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 535936-73-3P, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine 535936-74-4P, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3S,4S)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535936-73-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-tetrahydro-4-propoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-74-4 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3S,4S)-tetrahydro-4-propoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **535934-78-2P**, 5-(2,4-Dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine **535935-16-1P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine **535935-24-1P**, cis-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-1,2,3,4-tetrahydronaphthalen-2-ol **535935-76-3P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(cis-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine **535936-06-2P**, Benzyl cis-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate **535936-07-3P**, 5-(2,4-Dichlorophenyl)-N-(cis-4-ethoxypyrrolidin-3-yl)-3,6-diethylpyrazin-2-amine **535936-26-6P**, Benzyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate **535936-27-7P**, 5-(2,4-Dichlorophenyl)-N-((3R,4S)-4-ethoxypyrrolidin-3-yl)-3,6-diethylpyrazin-2-amine **535936-29-9P**, Benzyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate **535936-30-2P** **535936-36-8P**, Methyl (3R,4S)-3-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate **535936-39-1P**, Benzyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-hydroxypyrrolidine-1-carboxylate **535936-41-5P**, Benzyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate **535936-42-6P**, 5-(2-Chloro-4-methoxyphenyl)-N-((3R,4S)-4-ethoxypyrrolidin-3-yl)-3,6-diethylpyrazin-2-amine **535936-45-9P** **535938-32-0P**, Methyl 3-(2,4-dichlorophenyl)-6-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrazine-2-carboxylate
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535934-78-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-16-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-6-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-24-1 CAPLUS
CN 2-Naphthalenol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-1,2,3,4-tetrahydro-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-76-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-ethyl-2,3-dihydro-6-methoxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-06-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-07-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(3R,4S)-4-ethoxy-3-pyrrolidinyl]-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-26-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-27-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(3R,4S)-4-ethoxy-3-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-29-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, phenylmethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-30-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-36-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-39-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-hydroxy-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-41-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-42-6 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(3R,4S)-4-ethoxy-3-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-45-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-32-0 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **535934-30-6P**, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine **535934-31-7P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-32-8P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-36-2P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1S,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-39-5P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-40-8P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-N-methylpyrazin-2-amine **535934-43-1P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-44-2P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-N-methylpyrazin-2-amine **535934-45-3P**, N-[(1R,2S)-2-(Cyclopropylmethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine **535934-46-4P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(prop-2-ynyloxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-47-5P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-methoxyethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-48-6P**, N-[(1R,2S)-2-(Allyloxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine **535934-49-7P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-50-0P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-propoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-51-1P**, 2-[[[(1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl]oxy]ethanol **535934-53-3P**, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl dimethylcarbamate **535934-54-4P**, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl acetate **535934-56-6P**, 5-(2-Chloro-4-methoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine **535934-57-7P**, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-58-8P**, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl acetate **535934-60-2P**, N-[(1R,2S)-2-Ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine **535934-61-3P**, 3,6-Diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine **535934-63-5P**, 5-(2,4-Dimethoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine **535934-64-6P**, 5-(2,4-Dimethoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-67-9P**, 5-[2-Chloro-4-(dimethylamino)phenyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine **535934-68-0P**, 5-[2-Chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine **535934-71-5P**, 5-[6-(Dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine **535934-74-8P**, 5-(2,4-Dichlorophenyl)-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine **535934-75-9P**, N-(2,3-Dihydro-1H-inden-1-yl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethylpyrazin-2-amine **535934-79-3P**, 5-(4-Methoxy-2-methylphenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine **535934-83-9P**, N-[5-(2,4-Dichlorophenyl)-3,6-dimethylpyrazin-2-yl]isoquinolin-1-amine **535934-87-3P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(3-ethyl-6-methylpyridin-2-yl)pyrazin-2-amine **535934-88-4P**, 5-(2,4-Dichlorophenyl)-N-(4,6-dimethylpyridin-2-yl)-3,6-diethylpyrazin-2-amine **535934-91-9P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine **535934-93-1P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(5-methyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine **535934-98-6P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(cis-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine **535934-99-7P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(trans-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine **535935-02-5P**, 5-(2,4-Dichlorophenyl)-N-(3,4-dihydro-2H-thiochromen-4-yl)-3,6-diethylpyrazin-2-amine **535935-05-8P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine **535935-06-9P**, 2-(2,4-Dichlorophenyl)-3,6-diethyl-5-(1,2,3,4-tetrahydronaphthalen-1-yloxy)pyrazine **535935-09-2P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine **535935-10-5P**, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine **535935-13-8P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine **535935-20-7P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R*,2R*)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine **535935-21-8P**, 5-(2,4-Dichlorophenyl)-N-[(1R*,2R*)-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-3,6-diethylpyrazin-2-amine **535935-25-2P**, 5-(2,4-Dichlorophenyl)-N-(cis-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-3,6-diethylpyrazin-2-amine **535935-26-3P**, 5-(2,4-Dichlorophenyl)-N-(cis-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-3,6-diethylpyrazin-2-amine **535935-29-6P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine **535935-32-1P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Cis-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine **535935-33-2P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Trans-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine **535935-35-4P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Cis-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine **535935-37-6P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Trans-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine **535935-42-3P**, 5-(2,4-Dichlorophenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine **535935-43-4P**, 5-(2-Chloro-4-methylphenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine **535935-44-5P**, N-(3,4-Dihydro-2H-chromen-4-yl)-5-(2,4-dimethylphenyl)-3,6-diethylpyrazin-2-amine **535935-53-6P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine **535935-54-7P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine **535935-58-1P**, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine **535935-59-2P**, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine **535935-60-5P**, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine **535935-64-9P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine **535935-67-2P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine **535935-79-6P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(5-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine **535935-82-1P**, N-[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine **535935-87-6P**, N-[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine **535935-93-4P**, cis-N-[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine **535935-99-0P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(cis-2-ethyl-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine **535936-00-6P**, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(trans-2-ethyl-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine **535936-08-4P**, N-(cis-1-Acetyl-4-ethoxypyrrolidin-3-yl)-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine **535936-09-5P**, 5-(2,4-Dichlorophenyl)-N-(cis-4-ethoxy-1-propionylpyrrolidin-3-yl)-3,6-diethylpyrazin-2-amine **535936-10-8P**, Methyl cis-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate **535936-11-9P**, 5-(2,4-Dichlorophenyl)-N-(cis-4-ethoxy-1-(methylsulfonyl)pyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine **535936-12-0P**, Ethyl cis-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate **535936-13-1P**, cis-3-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxy-N,N-dimethylpyrrolidine-1-carboxamide

535936-14-2P, cis-3-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxy-N,N-dimethylpyrrolidine-1-carbothioamide
535936-15-3P, Isopropyl cis-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate
535936-16-4P, cis-3-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxy-N-methylpyrrolidine-1-carbothioamide
535936-17-5P, 5-(2,4-Dichlorophenyl)-N-[cis-4-ethoxy-1-(morpholin-4-ylcarbonyl)pyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine
535936-18-6P, 2-Fluoroethyl cis-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate
535936-28-8P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate
535936-31-3P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535936-37-9P, Methyl (3R,4S)-3-[[5-(2-chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535936-40-4P, Benzyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate
535936-44-8P, Methyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate
535936-46-0P, Methyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535936-51-7P, trans-N-(4-Ethoxytetrahydrofuran-3-yl)-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine
535936-57-3P, cis-N-(4-Ethoxytetrahydrofuran-3-yl)-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine
535936-67-5P, cis-5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-(4-methoxytetrahydrofuran-3-yl)pyrazin-2-amine
535936-69-7P, cis-5-(2-Chloro-4-methoxyphenyl)-N-(4-ethoxytetrahydrofuran-3-yl)-3,6-diethylpyrazin-2-amine
535936-76-6P, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[cis-4-(3-fluoropropoxy)tetrahydrofuran-3-yl]pyrazin-2-amine
535936-84-6P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(1-propyl-1H-imidazol-2-yl)pyrazin-2-amine
535937-81-6P, 3,6-Dicyclopropyl-5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine
535937-84-9P, 6-Cyclopropyl-5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-methylpyrazin-2-amine
535937-87-2P, 3-Cyclopropyl-5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-methylpyrazin-2-amine
535937-90-7P, 6-Cyclopropyl-5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethylpyrazin-2-amine
535937-92-9P, 5-(2-Chloro-4-methoxyphenyl)-6-cyclopropyl-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethylpyrazin-2-amine
535937-94-1P, 6-Cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine
535937-96-3P, 3-Cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine
535937-98-5P, 3-Cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine
535938-00-2P, 5-(2-Chloro-4-methoxyphenyl)-3-cyclopropyl-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethylpyrazin-2-amine
535938-01-3P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-methylpyrazin-2-amine
535938-03-5P, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-methylpyrazin-2-amine
535938-08-0P, (1R,2R)-N1-(3,6-Dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl)-N2-ethyl-2,3-dihydro-1H-indene-1,2-diamine
535938-10-4P, N-[(1R,2R)-1-[[3,6-Dicyclopropyl-5-(2,4-dichlorophenyl]pyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl]acetamide
535938-12-6P, (1R,2R)-N1-(3,6-Dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl)-N2-(2-methoxyethyl)-2,3-dihydro-1H-indene-1,2-diamine
535938-14-8P, 5-(2,4-Dichlorophenyl)-N-((1S,2R)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine
535938-16-0P, 5-(2,4-Dichlorophenyl)-N-((1S,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine
535938-18-2P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535938-36-4P, Methyl 6-[[(1R,2S)-2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl]amino]-3-(2,4-dichlorophenyl)-5-methoxypyrazine-2-carboxylate
535938-47-7P, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy-3-vinylpyrazin-2-amine
535938-49-9P, Methyl (3S,4R)-3-(acetyloxy)-4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]pyrrolidine-1-carboxylate
535938-51-3P, Methyl (3S,4R)-3-(acetyloxy)-4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]pyrrolidine-1-carboxylate
535938-53-5P, Ethyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535938-55-7P, Ethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535938-59-1P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-propoxypyrrolidine-1-carboxylate
535938-62-6P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate
535938-65-9P, Methyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate
535938-68-2P, Methyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-propoxypyrrolidine-1-carboxylate
535938-70-6P, Methyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(propionyloxy)pyrrolidine-1-carboxylate
535938-73-9P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(propionyloxy)pyrrolidine-1-carboxylate
535938-76-2P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(propionylamino)pyrrolidine-1-carboxylate
535938-79-5P, Methyl (3S,4R)-3-(acetylamino)-4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]pyrrolidine-1-carboxylate
535938-82-0P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(ethylamino)pyrrolidine-1-carboxylate
535938-85-3P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(propylamino)pyrrolidine-1-carboxylate
535938-87-5P, O-Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carbothioate
535938-88-6P, O-Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carbothioate
535938-90-0P, O-Methyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(3-fluoropropoxy)pyrrolidine-1-carbothioate
535938-92-2P, Pyridin-2-ylmethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535938-94-4P, Pyridin-3-ylmethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535938-96-6P, Pyridin-4-ylmethyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535938-98-8P, 2-Piperidin-1-ylethyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-00-5P, 2-Morpholin-4-ylethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl]-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-02-7P, 2-Morpholin-4-ylethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(propionyloxy)pyrrolidine-1-carboxylate
535939-03-8P, 2-(Dimethylamino)ethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate
535939-06-1P, 2-Pyrrolidin-1-ylethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate
535939-07-2P, 2-(1H-Imidazol-1-yl)ethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl]-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-09-4P, 2-(Methylamino)ethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-11-8P, 2-Aminoethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-13-0P, 2-Hydroxyethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-15-2P, 2-Methoxyethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-17-4P, 2-(2-Oxopyrrolidin-1-yl)ethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate
535939-18-5P, 2-(2-Oxopyridin-1(2H)-yl)ethyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate
535939-20-9P, (3S,4S)-3-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidin-2-one
535939-22-1P, (3S,4S)-3-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxy-1-methylpyrrolidin-2-one
535939-24-3P, (3S,4S)-1-Benzyl-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidin-2-one
535939-26-5P, (3R,4R)-4-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-3-(2-fluoroethoxy)pyrrolidin-2-one
535939-28-7P, (3R,4R)-4-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-3-(2-fluoroethoxy)-1-methylpyrrolidin-2-one
535939-30-1P, (3R,4R)-1-Benzyl-4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-3-(2-fluoroethoxy)pyrrolidin-2-one
535939-32-3P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(1-ethyl-1H-imidazol-2-yl)pyrazin-2-amine
535939-34-5P, Ethyl (2S,3S)-3-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl]pyrazin-2-yl]amino]-2,3-dihydrofuro[2,3-b]pyridine-2-carboxylate
535939-36-7P, (2S,3S)-N-[3,6-Diethyl-5-(4-methoxy-2-methylphenyl]pyrazin-2-yl]-2-(ethoxymethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine
535939-38-9P, (2R,3S)-N-[3,6-Diethyl-5-(4-methoxy-2-methylphenyl]pyrazin-2-yl]-2-ethyl-2,3-dihydrofuro[2,3-b]pyridin-3-amine
535939-40-3P, (2R,3S)-N-[3,6-Diethyl-5-(4-methoxy-2-methylphenyl]pyrazin-2-yl]-2-propyl-2,3-dihydrofuro[2,3-b]pyridin-3-amine
535939-42-5P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine
535939-43-6P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine
535939-45-8P, 5-(2,4-Dichlorophenyl)-N-[(2R)-2-(ethoxymethyl)pyrrolidin-1-yl]-3,6-diethylpyrazin-2-amine
535939-47-0P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(propoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine
535939-49-2P, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[(2R)-2-[(2-fluoroethoxy)methyl]pyrrolidin-1-yl]pyrazin-2-amine
535939-51-6P, 5-(2-Chloro-4-methoxyphenyl)-N-[(2R)-2-(ethoxymethyl)pyrrolidin-1-yl]-3,6-diethylpyrazin-2-amine
535939-53-8P, 5-(2-Chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)pyrazin-2-amine
535939-55-0P, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)pyrazin-2-amine
535939-57-2P, Methyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-bis(methoxymethyl]pyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-59-4P, Methyl (3R,4S)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-bis(methoxymethyl]pyrazin-2-yl]amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate
535939-61-8P, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535939-63-0P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535939-65-2P, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl hydroxyacetate
535939-67-4P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl hydroxyacetate
535939-68-5P, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl methoxyacetate
535939-70-9P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl methoxyacetate
535939-72-1P, N-[(1R,2S)-2-(2-Aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-amine
535939-74-3P, N-[(1R,2S)-2-(2-Aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine
535939-76-5P, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl glycinate
535939-78-7P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl glycinate
535939-80-1P, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-[2-(methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535939-82-3P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-[2-(methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535939-84-5P, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl N-methylglycinate
535939-86-7P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl N-methylglycinate
535939-88-9P, 5-(2-Chloro-4-methoxyphenyl)-N-[(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine
535939-90-3P, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine
535939-92-5P, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl N,N-dimethylglycinate
535939-93-6P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl N,N-dimethylglycinate
535939-95-8P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl methylcarbamate
535939-97-0P, 5-(4-Chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535940-02-4P, (1R,2S)-1-[[5-(4-Chloro-2-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl acetate
535940-07-9P, 5-(4-Chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535940-09-1P, (3R,4R)-4-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]tetrahydrofuran-3-yl acetate
535940-11-5P, (3R,4R)-4-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]tetrahydrofuran-3-yl acetate
535940-13-7P, (3R,4R)-4-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]tetrahydrofuran-3-yl propionate
535940-15-9P, (3R,4R)-4-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]tetrahydrofuran-3-yl propionate
535940-16-0P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-((3R,4R)-4-propoxytetrahydrofuran-3-yl)pyrazin-2-amine
535940-18-2P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydrofuran-3-yl]pyrazin-2-amine
535940-20-6P, (3S,4R)-3-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(2-fluoroethoxy)dihydrofuran-2(3H)-one
535940-22-8P, (3S,4R)-3-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxydihydrofuran-2(3H)-one
535940-24-0P, (3R,4S)-4-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-5-oxotetrahydrofuran-3-yl acetate
535940-26-2P, (3R,4S)-4-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-5-oxotetrahydrofuran-3-yl propionate
535940-28-4P, (3S,4R)-3-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-propoxydihydrofuran-2(3H)-one
535940-30-8P, (3S,4R)-3-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-(3-fluoropropoxy)dihydrofuran-2(3H)-one
535940-32-0P, (1R,2S)-N-[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]-N'-ethyl-2,3-dihydro-1H-indene-1,2-diamine
535940-34-2P
535940-36-4P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-dimethoxypyrazin-2-amine
535940-38-6P, 3-Cyclopropyl-5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-methoxypyrazin-2-amine
535940-40-0P, 3-(2,4-Dichlorophenyl)-6-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-ethylpyrazine-2-carboxamide
535940-42-2P, 3-(2,4-Dichlorophenyl)-6-[((1R,2S)-2-

ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxamide
535940-44-4P, 3-(2,4-Dichlorophenyl)-6-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-(methylthio)pyrazine-2-carboxamide
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535934-30-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-31-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-32-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(1-methylethoxy)-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-36-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2R)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 535934-39-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-40-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-diethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-43-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2R)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-44-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2R)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-diethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-45-3 CAPLUS
CN Pyrazinamine, N-[(1R,2S)-2-(cyclopropylmethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-46-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(2-propynyloxy)-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-47-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(2-methoxyethoxy)-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-50-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-propoxy-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-51-1 CAPLUS
CN Ethanol, 2-[[(1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-48-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(2-propenyloxy)-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-49-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-53-3 CAPLUS
CN Carbamic acid, dimethyl-, (1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 535934-54-4 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 535934-56-6 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-57-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-61-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-63-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-58-8 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 535934-60-2 CAPLUS
CN Pyrazinamine, N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-64-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-67-9 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-60-0 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-71-5 CAPLUS
CN Pyrazinamine, 5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-83-9 CAPLUS
CN 1-Isoquinolinamine, N-[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 535934-87-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(3-ethyl-6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 535934-88-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(4,6-dimethyl-2-pyridinyl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535934-74-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 535934-75-9 CAPLUS
CN Pyrazinamine, N-(2,3-dihydro-1H-inden-1-yl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 535934-79-3 CAPLUS
CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 535934-91-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-4-benzofuranyl)- (9CI) (CA INDEX NAME)



RN 535934-93-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-5-methyl-4-benzofuranyl)- (9CI) (CA INDEX NAME)



RN 535934-98-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-5-ethyl-4,5,6,7-tetrahydro-4-benzofuranyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535934-99-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-5-ethyl-4,5,6,7-tetrahydro-4-benzofuranyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-02-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-1-benzothiopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)





RN 535935-10-5 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-13-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)

RN 535935-05-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-06-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)



RN 535935-09-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-20-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-1,2,3,4-tetrahydro-2-methoxy-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-21-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2R)-2-ethoxy-1,2,3,4-tetrahydro-1-naphthalenyl]-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-25-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-1,2,3,4-tetrahydro-2-methoxy-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-26-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-1,2,3,4-tetrahydro-1-naphthalenyl]-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 535935-35-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-5-ethyl-4,5,6,7-tetrahydrobenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-37-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-5-ethyl-4,5,6,7-tetrahydrobenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-29-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydrobenzo[b]thien-4-yl)- (9CI) (CA INDEX NAME)



RN 535935-32-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-4,5,6,7-tetrahydro-5-methylbenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-33-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-4,5,6,7-tetrahydro-5-methylbenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 535935-42-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-1-benzopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535935-43-4 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-N-(3,4-dihydro-2H-1-benzopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535935-44-5 CAPLUS
CN Pyrazinamine, N-(3,4-dihydro-2H-1-benzopyran-4-yl)-5-(2,4-dimethylphenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535935-53-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-4,5,6,7-tetrahydro-5-propylbenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-54-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-4,5,6,7-tetrahydro-5-propylbenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-60-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(1-methylethoxy)-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535935-64-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-8-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-50-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535935-59-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535935-67-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-6-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535935-79-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-5-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535935-82-1 CAPLUS
CN 5H-Cyclopenta[b]pyridin-7-amine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-6,7-dihydro- (9CI) (CA INDEX NAME)



RN 535935-87-6 CAPLUS
CN 5H-Cyclopenta[b]pyridin-5-amine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-6,7-dihydro- (9CI) (CA INDEX NAME)



RN 535935-93-4 CAPLUS
CN 5H-Cyclopenta[b]pyridin-7-amine, N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]-6-ethyl-6,7-dihydro-, (6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-99-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-ethyl-2,3-dihydro-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-00-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-ethyl-2,3-dihydro-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-11-9 CAPLUS
CN 3-Pyrrolidinamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-1-(methylsulfonyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-12-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, ethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-13-1 CAPLUS
CN 1-Pyrrolidinecarboxamide, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-N,N-dimethyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-08-4 CAPLUS
CN 3-Pyrrolidinamine, 1-acetyl-N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-09-5 CAPLUS
CN 3-Pyrrolidinamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-1-(1-oxopropyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-10-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, methyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-14-2 CAPLUS
CN 1-Pyrrolidinecarbothioamide, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-N,N-dimethyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-15-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, 1-methylethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-16-4 CAPLUS
CN 1-Pyrrolidinecarbothioamide, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-N-methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-17-5 CAPLUS
CN Morpholine, 4-[[(3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-1-pyrrolidinyl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-18-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, 2-fluoroethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-28-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-31-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-37-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-40-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-44-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-46-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-51-7 CAPLUS
CN Pyrazinamine, N-[(3R,4S)-4-ethoxytetrahydro-3-furanyl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-57-3 CAPLUS
CN Pyrazinamine, N-[(3R,4R)-4-ethoxytetrahydro-3-furanyl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-67-5 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-tetrahydro-4-methoxy-3-furanyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-69-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(3R,4R)-4-ethoxytetrahydro-3-furanyl]-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-76-6 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydro-3-furanyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-84-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-propyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 535937-81-6 CAPLUS
CN Pyrazinamine, 3,6-dicyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-84-9 CAPLUS
CN Pyrazinamine, 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-87-2 CAPLUS
CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-90-7 CAPLUS
CN Pyrazinamine, 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-92-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-94-1 CAPLUS
CN Pyrazinamine, 6-cyclopropyl-5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-96-3 CAPLUS
CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-98-5 CAPLUS
CN Pyrazinamine, 3-cyclopropyl-5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-00-2 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-08-0 CAPLUS
CN 1H-Indene-1,2-diamine, N1-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]-N2-ethyl-2,3-dihydro-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-10-4 CAPLUS
CN Acetamide, N-[(1R,2R)-1-[[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-01-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-03-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-12-6 CAPLUS
CN 1H-Indene-1,2-diamine, N1-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]-2,3-dihydro-N2-(2-methoxyethyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-14-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2R)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-16-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-18-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-49-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(acetyloxy)-4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-, methyl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-51-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(acetyloxy)-4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-, methyl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-53-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)



RN 535938-36-4 CAPLUS
CN Pyrazinecarboxylic acid, 6-[[(1R,2S)-2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl]amino]-3-(2,4-dichlorophenyl)-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-47-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethenyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-55-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-59-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-propoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-62-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-65-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-68-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-propoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-70-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(1-oxopropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-82-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(ethylamino)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-85-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(propylamino)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-87-5 CAPLUS
CN 1-Pyrrolidinecarbothioic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-73-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(1-oxopropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-76-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-[(1-oxopropyl)amino]-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-79-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(acetylamino)-4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-, methyl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-88-6 CAPLUS
CN 1-Pyrrolidinecarbothioic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-90-0 CAPLUS
CN 1-Pyrrolidinecarbothioic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-92-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 2-pyridinylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-94-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 3-pyridinylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-96-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 4-pyridinylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-98-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 2-(1-piperidinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)



RN 535939-06-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, 2-(1-pyrrolidinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-07-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 2-(1H-imidazol-1-yl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 535939-00-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 2-(4-morpholinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-02-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(1-oxopropoxy)-, 2-(4-morpholinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-03-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, 2-(dimethylamino)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-09-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 2-(methylamino)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-11-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 2-aminoethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-13-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 2-hydroxyethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-15-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, 2-methoxyethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-17-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-10-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, 2-(2-oxo-1(2H)-pyridinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-24-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-1-(phenylmethyl)-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-26-5 CAPLUS
CN 2-Pyrrolidinone, 4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-3-(2-fluoroethoxy)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-20-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-22-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-1-methyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-28-7 CAPLUS
CN 2-Pyrrolidinone, 4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-3-(2-fluoroethoxy)-1-methyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-30-1 CAPLUS
CN 2-Pyrrolidinone, 4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-3-(2-fluoroethoxy)-1-(phenylmethyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-32-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 535939-34-5 CAPLUS
CN Furo[2,3-b]pyridine-2-carboxylic acid, 3-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]amino]-2,3-dihydro-, ethyl ester, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-36-7 CAPLUS
CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2-(ethoxymethyl)-2,3-dihydro-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-38-9 CAPLUS
CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2-ethyl-2,3-dihydro-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-40-3 CAPLUS
CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2,3-dihydro-2-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-42-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-43-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-45-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(2R)-2-(ethoxymethyl)-1-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-47-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(propoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-49-2 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(2R)-2-[(2-fluoroethoxy)methyl]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-51-6 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(2R)-2-(ethoxymethyl)-1-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-53-8 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-55-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-57-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-bis(methoxymethyl)pyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-59-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-bis(methoxymethyl)pyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-61-8 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-63-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-65-2 CAPLUS
CN Acetic acid, hydroxy-, (1R,2S)-1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-67-4 CAPLUS
CN Acetic acid, hydroxy-, (1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-68-5 CAPLUS
CN Acetic acid, methoxy-, (1R,2S)-1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-70-9 CAPLUS
CN Acetic acid, methoxy-, (1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-72-1 CAPLUS
CN Pyrazinamine, N-[(1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-74-3 CAPLUS
CN Pyrazinamine, N-[(1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-80-1 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2,3-dihydro-2-[2-(methylamino)ethoxy]-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-82-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-[2-(methylamino)ethoxy]-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-76-5 CAPLUS
CN Glycine, (1R,2S)-1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-78-7 CAPLUS
CN Glycine, (1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-84-5 CAPLUS
CN Glycine, N-methyl-, (1R,2S)-1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-86-7 CAPLUS
CN Glycine, N-methyl-, (1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-88-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-90-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-95-8 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, methylcarbamate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-97-0 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-92-5 CAPLUS
CN Glycine, N,N-dimethyl-, (1R,2S)-1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-93-6 CAPLUS
CN Glycine, N,N-dimethyl-, (1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-02-4 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(4-chloro-2-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-07-9 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-09-1 CAPLUS
CN 3-Furanol, 4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, acetate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-11-5 CAPLUS
CN 3-Furanol, 4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, acetate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-13-7 CAPLUS
CN 3-Furanol, 4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, propanoate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-15-9 CAPLUS
CN 3-Furanol, 4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, propanoate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-16-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-tetrahydro-4-propoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-18-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydro-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-20-6 CAPLUS
CN 2(3H)-Furanone, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)dihydro-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-22-8 CAPLUS
CN 2(3H)-Furanone, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxydihydro-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-24-0 CAPLUS
CN 2(3H)-Furanone, 4-(acetyloxy)-3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]dihydro-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-26-2 CAPLUS
CN 2(3H)-Furanone, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]dihydro-4-(1-oxopropoxy)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-28-4 CAPLUS
CN 2(3H)-Furanone, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]dihydro-4-propoxy-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-30-8 CAPLUS
CN 2(3H)-Furanone, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)dihydro-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-36-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-38-6 CAPLUS
CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-32-0 CAPLUS
CN 1H-Indene-1,2-diamine, N1-(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N2-ethyl-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-34-2 CAPLUS
CN Acetamide, N-[(1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-40-0 CAPLUS
CN Pyrazinecarboxamide, 3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino)-5-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-42-2 CAPLUS
CN Pyrazinecarboxamide, 3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino)-5-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-44-4 CAPLUS
CN Pyrazinecarboxamide, 3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 535940-46-6P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-(methylthio)pyrazin-2-amine
535940-48-8P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-methoxypyrazin-2-amine
535940-50-2P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-methoxypyrazin-2-amine
535940-52-4P, 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-(methylthio)pyrazin-2-amine
535940-54-6P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-bis(methylthio)pyrazin-2-amine
535940-56-8P, 6-(2,4-Dichlorophenyl)-3-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-ethylpyrazine-2-carboxamide
535940-58-0P, 6-(2,4-Dichlorophenyl)-3-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrazine-2-carboxamide
535940-60-4P, 6-(2,4-Dichlorophenyl)-3-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-(methylthio)pyrazine-2-carboxamide
535940-61-5P, 5-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-N'-methylpyrazine-2,3-diamine
535940-63-7P, 6-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-N',N''-dimethylpyrazine-2,3,5-triamine
535940-65-9P, 3-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-5-ethyl-N'-methylpyrazine-2,6-diamine
535940-71-7P, trans-N-[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535940-46-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-48-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-50-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-52-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-54-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-56-8 CAPLUS
CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-58-0 CAPLUS
CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-60-4 CAPLUS
CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-65-9 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-5-ethyl-N6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-71-7 CAPLUS
CN 5H-Cyclopenta[b]pyridin-7-amine, N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]-6-ethyl-6,7-dihydro-, (6R,7S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **535936-43-7**, (3R,4S)-3-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate **535938-34-2**, Methyl 3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxypyrazine-2-carboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)



RN 535940-61-5 CAPLUS
CN 2,3-Pyrazinediamine, 5-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-N3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-63-7 CAPLUS
CN Pyrazinetriamine, 6-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-N3,N5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

(preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535936-43-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-34-2 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **535934-29-3P**, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535934-35-1P**, (1S,2R)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535934-37-3P**, (1S,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate **535934-38-4P**, (1S,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535934-41-9P**, (1R,2R)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate **535934-42-0P**, (1R,2R)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535934-52-2P** **535934-55-5P**, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535934-59-9P**, (1R,2S)-1-[(3,6-Diethyl-5-(4-methoxy-2-methylphenyl]pyrazin-2-yl]amino)-2,3-dihydro-1H-inden-2-ol **535934-62-4P**, (1R,2S)-1-[[5-(2,4-Dimethoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535934-65-7P**, (1R,2S)-1-[[5-[2-Chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535934-69-1P**, (1R,2S)-1-[[5-[6-(Dimethylamino)-4-methylpyridin-3-yl]-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535935-19-4P**, trans-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-1,2,3,4-tetrahydronaphthalen-2-ol **535935-57-0P**, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-dimethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol **535936-03-9P**, Benzyl trans-3-[[5-(2,4-dichlorophenyl)-3,6-

diethylpyrazin-2-yl]amino]-4-hydroxypyrrolidine-1-carboxylate 535936-04-0P, Benzyl cis-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-[(4-nitrobenzoyl)oxy]pyrrolidine-1-carboxylate 535936-05-1P, Benzyl cis-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-hydroxypyrrolidine-1-carboxylate 535936-25-5P, Benzyl (3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-4-hydroxypyrrolidine-1-carboxylate 535936-49-3P, trans-4-[[3,6-Diethyl-5-(4-methoxy-2-methylphenyl]pyrazin-2-yl]amino]tetrahydrofuran-3-ol 535936-53-9P, cis-4-[[3,6-Diethyl-5-(4-methoxy-2-methylphenyl]pyrazin-2-yl]amino]tetrahydrofuran-3-yl 4-nitrobenzoate 535936-55-1P, cis-4-[[3,6-Diethyl-5-(4-methoxy-2-methylphenyl]pyrazin-2-yl]amino]tetrahydrofuran-3-ol 535936-65-3P, cis-4-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]tetrahydrofuran-3-ol 535937-53-2P, (1R,2S)-1-[[3,6-Dicyclopropyl-5-(2,4-dichlorophenyl]pyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-55-4P, (1R,2S)-1-[[6-Cyclopropyl-5-(2,4-dichlorophenyl)-3-methylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-58-7P, (1R,2S)-1-[[3-Cyclopropyl-5-(2,4-dichlorophenyl)-6-methylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-61-2P, (1R,2S)-1-[[6-Cyclopropyl-5-(2,4-dichlorophenyl)-3-ethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-63-4P, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-65-6P, (1R,2S)-1-[[6-Cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-3-ethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-67-8P, (1R,2S)-1-[[3-Cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-69-0P, (1R,2S)-1-[[3-Cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-6-ethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-72-5P, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3-cyclopropyl-6-ethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-75-8P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-6-ethyl-3-methylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535937-78-1P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3-ethyl-6-methylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535938-04-6P, N-((1R,2R)-2-Azido-2,3-dihydro-1H-inden-1-yl)-3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-amine 535938-06-8P, (1R,2R)-N1-[3,6-Dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-2,3-dihydro-1H-indene-1,2-diamine 535938-26-2P, Methyl 3-(2,4-dichlorophenyl)-6-[((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino]pyrazine-2-carboxylate 535938-28-4P, Methyl 5-bromo-3-(2,4-dichlorophenyl)-6-[((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino]pyrazine-2-carboxylate 535938-30-8P, Ethyl 3-(2,4-dichlorophenyl)-6-[((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrazine-2-carboxylate 535938-42-2P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-6-methoxypyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535938-43-3P, (1R,2S)-1-[[3-Bromo-5-(2,4-dichlorophenyl)-6-methoxypyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535938-45-5P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-6-methoxy-3-vinylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535934-29-3 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-35-1 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-37-3 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, 4-nitrobenzoate (ester), (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-38-4 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-41-9 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, 4-nitrobenzoate (ester), (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-42-0 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 535934-52-2 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-55-5 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-59-9 CAPLUS
CN 1H-Inden-2-ol, 1-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-62-4 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dimethoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-65-7 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2-chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-69-1 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535935-19-4 CAPLUS
CN 2-Naphthalenol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-1,2,3,4-tetrahydro-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-57-0 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-03-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-hydroxy-, phenylmethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-04-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-[(4-nitrobenzoyl)oxy]-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-05-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-hydroxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-25-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-hydroxy-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-49-3 CAPLUS
CN 3-Furanol, 4-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl]pyrazinyl]amino]tetrahydro-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-53-9 CAPLUS
CN 3-Furanol, 4-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl]pyrazinyl]amino]tetrahydro-, 4-nitrobenzoate (ester), (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-55-1 CAPLUS
CN 3-Furanol, 4-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]amino]tetrahydro-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-65-3 CAPLUS
CN 3-Furanol, 4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535937-53-2 CAPLUS
CN 1H-Inden-2-ol, 1-[[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-55-4 CAPLUS
CN 1H-Inden-2-ol, 1-[[6-cyclopropyl-5-(2,4-dichlorophenyl)-3-methylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-58-7 CAPLUS
CN 1H-Inden-2-ol, 1-[[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-methylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-67-8 CAPLUS
CN 1H-Inden-2-ol, 1-[[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-69-0 CAPLUS
CN 1H-Inden-2-ol, 1-[[3-cyclopropyl-5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-6-ethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-72-5 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-6-ethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-61-2 CAPLUS
CN 1H-Inden-2-ol, 1-[[6-cyclopropyl-5-(2,4-dichlorophenyl)-3-ethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-63-4 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-65-6 CAPLUS
CN 1H-Inden-2-ol, 1-[[6-cyclopropyl-5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-3-ethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-75-8 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-6-ethyl-3-methylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535937-78-1 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3-ethyl-6-methylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-04-6 CAPLUS
CN Pyrazinamine, N-[(1R,2R)-2-azido-2,3-dihydro-1H-inden-1-yl]-3,6-dicyclopropyl-5-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-06-8 CAPLUS
CN 1H-Indene-1,2-diamine, N1-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]-2,3-dihydro-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-26-2 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-28-4 CAPLUS
CN Pyrazinecarboxylic acid, 5-bromo-3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-30-8 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-42-2 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-6-methoxypyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-43-3 CAPLUS
CN 1H-Inden-2-ol, 1-[[3-bromo-5-(2,4-dichlorophenyl)-6-methoxypyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-45-5 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3-ethenyl-6-methoxypyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:554265 CAPLUS
DOCUMENT NUMBER: 137:243205
TITLE: Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity
AUTHOR(S): Cariello, Neal F.; Wilson, John D.; Britt, Ben H.; Wedd, David J.; Burlinson, Brian; Gombar, Vijay
CORPORATE SOURCE: Safety Assessment, GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA
SOURCE: Mutagenesis (2002), 17(4), 321-329
CODEN: MUTAEX; ISSN: 0267-8357
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The performance of two computer programs, DEREK and TOPKAT, was examined with regard to predicting the outcome of the Ames bacterial mutagenicity assay. The results of over 400 Ames tests conducted at Glaxo Wellcome (now GlaxoSmithKline) during the last 15 yr on a wide variety of chemical classes were compared with the mutagenicity predictions of both computer programs. DEREK was considered concordant with the Ames assay if (i) the Ames assay was neg. (not mutagenic) and no structural alerts for mutagenicity were identified or (ii) the Ames assay was pos. (mutagenic) and at least one structural alert was identified. Conversely, the DEREK output was considered discordant if (i) the Ames assay was neg. and any structural alert was identified or (ii) the Ames assay was pos. and no structural alert was identified. The overall concordance of the DEREK program with the Ames results was 65% and the overall discordance was 35%, based on over 400 compds. About 23% of the test mols. were outside the permissible limits of the optimum prediction space of TOPKAT. Another 4% of the compds. were either not processable or had indeterminate mutagenicity predictions; these mols. were excluded from the TOPKAT anal. If the TOPKAT probability was (i) ≥0.7 the mol. was predicted to be mutagenic, (ii) ≤0.3 the compound was predicted to be non-mutagenic and (iii) between 0.3 and 0.7 the prediction was considered indeterminate. From over 300 acceptable predictions, the overall TOPKAT concordance was 73% and the overall discordance was 27%. While the overall concordance of the TOPKAT program was higher than DEREK, TOPKAT fared more poorly than DEREK in the critical Ames-pos. category, where 60% of the compds. were incorrectly predicted by TOPKAT as neg. but were mutagenic in the Ames test. For DEREK, 54% of the Ames-pos. mols. had no structural alerts and were predicted to be non-mutagenic. Alternative methods of analyzing the output of the programs to increase the accuracy with Ames-pos. compds. are discussed.

IT 212778-82-0
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(computer programs DEREK and TOPKAT to predict bacterial mutagenicity)
RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:487401 CAPLUS
DOCUMENT NUMBER: 137:47125
TITLE: N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5 receptor antagonists
INVENTOR(S): Stamford, Andrew W.; Dong, Youhao; McCombie, Stuart W.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049648	A1	20020627	WO 2001-US49302	20011217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432809	AA	20020627	CA 2001-2432809	20011217
AU 2002034056	A5	20020701	AU 2002-34056	20011217
EP 1343503	A1	20030917	EP 2001-985069	20011217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

ER 2001016379	A	20030930	BR 2001-16379		20011217
JP 2004516267	T2	20040603	JP 2002-550988		20011217
NZ 526174	A	20041224	NZ 2001-526174		20011217
ZA 2003004348	A	20040909	ZA 2003-4348		20030603
NO 2003002861	A	20030821	NO 2003-2861		20030620
PRIORITY APPLN. INFO.:			US 2000-257308P	P	20001221
			WO 2001-US49302	W	20011217

OTHER SOURCE(S): MARPAT 137:47125

AB RZKHCOMeZ1R1 (I; R = fluorophenyl; R1 = alkanoyl, alkylsulfonyl, pyridinyl(carbonyl), etc.; Z = pyridine-, pyrazine-, or pyrimidine-2,5-diyl, etc.; Z1 = e.g., piperidine-4,1-diyl] were prepared Thus, 3,5-F2C6H3B(OH)2 was condensed with 2-bromo-5-nitropyridine and the reduced product condensed with COCl2 and N-methyl-1-(2-pyridinyl)piperidine-4-amine to give I (R = C6H3F2-3,5, R1 = 2-pyridinyl, Z = pyridine-2,5-diyl, Z1 = piperidine-4,1-diyl). Data for biol. activity of I were given.

IT **438584-80-6P 438584-81-7P 438584-82-8P**
438584-83-9P 438584-84-0P 438584-96-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(n-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5 receptor antagonists)

RN 438584-80-6 CAPLUS
CN 4-Piperidinamine, 1-acetyl-N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 438584-81-7 CAPLUS
CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 438584-82-8 CAPLUS
CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 438584-83-9 CAPLUS
CN 4-Piperidinamine, 1-(cyclopropylcarbonyl)-N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 438584-84-0 CAPLUS
CN 4-Piperidinamine, 1-(cyclopentylcarbonyl)-N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 438584-96-4 CAPLUS
CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:193584 CAPLUS
DOCUMENT NUMBER: 137:41243
TITLE: N-O glucuronidation: a major human metabolic pathway in the elimination of two novel anti-convulsant drug candidates

AUTHOR(S): Ismail, I. M.; Dear, G. J.; Roberts, A. D.; Plumb, R. S.; Ayrton, J.; Sweatman, B. C.; Bowers, G. D.
CORPORATE SOURCE: Structural Identification Group, GlaxoSmithKline Research and Development, Ware, SG12 0DP, UK
SOURCE: Xenobiotica (2002), 32(1), 29-43
CODEN: XENOBH; ISSN: 0049-8254
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The urinary metabolites of the anti-convulsant compound 4-amino-1-(2,6-difluorobenzyl)-1H-1,2,3-triazolo[4,5-c]-pyridine hydrochloride (GI265080) obtained following a single oral dose to man have been detected and quantified relative to each other using 19F-NMR spectroscopy. The human urinary metabolites of GI265080 were isolated using semipreparative HPLC and unequivocally characterized using 1H-NMR spectroscopy, two-dimensional heteronuclear NMR spectroscopy and mass spectrometry. The assignments of the N-(5)-oxide and the N-(5)-O-glucuronide metabolites of GI265080 were further confirmed by independent synthesis. The urinary metabolites obtained following single oral doses to dog and rat have also been isolated and characterized. The human urinary metabolites of GI265080 comprise the N-(5)-oxide, the quaternary N+-(5)-glucuronide, the 7-hydroxy glucuronide and a glucuronide conjugate of the N-(5)-oxide. The N-(5)-O-glucuronide conjugate is a novel species in human metabolism and is a significant route of elimination of GI265080 in man. The urinary metabolites of the potential anti-convulsant GW273293 (6-amino-3-(2,3,5-trichlorophenyl)pyrazin-2-ylamine) obtained following a single oral dose to man have also been isolated and characterized. The formation of a novel N-O-glucuronide was also observed and was shown to constitute a significant route of elimination of GW273293 in man.

IT **212778-82-0, GW 273293 437651-94-0 437651-96-2**
437651-97-3 438553-55-0, GW 412646
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(N-O glucuronidation, a major human metabolic pathway in elimination of two novel anti-convulsant drug candidates)

RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 437651-94-0 CAPLUS
CN Pyrazinium, 2,6-diamino-1-(β-D-glucopyranuronosyloxy)-3-(2,3,5-trichlorophenyl)-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 437651-96-2 CAPLUS
CN 2(1H)-Pyrazinone, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 437651-97-3 CAPLUS
CN β-D-Glucopyranosiduronic acid, 3,5-diamino-6-(2,3,5-trichlorophenyl)pyrazinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438553-55-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)-, 1-oxide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:10467 CAPLUS
DOCUMENT NUMBER: 136:69823
TITLE: Preparation of imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
INVENTOR(S): Konno, Fujiko; Nagao, Yoshihiro; Isomae, Kazuo; Ohtsuka, Mari; Takahashi, Yoshiyuki; Ishii, Fumio; Hirota, Hiroyuki; Takeda, Sunao; Kawamoto, Noriyuki; Honda, Haruyoshi; Sato, Susumu
PATENT ASSIGNEE(S): Ssp Co., Ltd., Japan
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000648	A1	20020103	WO 2001-JP4836	20010608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001064223	A5	20020108	AU 2001-64223	20010608
CA 2410391	AA	20021128	CA 2001-2410391	20010608
EP 1295880	A1	20030326	EP 2001-938563	20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003207896	A1	20031106	US 2002-258610	20021105
PRIORITY APPLN. INFO.:			JP 2000-194024 A	20000628
			WO 2001-JP4836 W	20010608

OTHER SOURCE(S): MARPAT 136:69823
GI



I



II

AB Title compds. [I; R1, R2 each independently = aryl, heteroaryl; A, Y1, Y2 each independently = N, CH; Y, Z each independently = O, S, NH, SO2, CH2, NCH3; R3, R4, R5 each independently = H, alkyl, NH2, alkoxy, Cl; n = 1, 2, 3, 4; n = 0, 1, 2, 3, 4] and salts are prepared and formulation discussed. Title compds. I exhibit excellent inhibitory activities against the production of NO and IL-6 and are useful in the prevention or treatment of diseases resulting from over-development of NO and IL-6. Thus, the title compound II was prepared and tested as antiinflammatory in male ICR mouse with inhibition result at 30.5% for 3 mg/kg dosage.
IT 385413-98-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. or salts thereof and drugs containing derivs.
or salts)
RN 385413-98-9 CAPLUS
CN Pyrazine, 2-(2,4-difluorophenyl)-5-[2-[4-(1H-imidazol-1-ylmethyl)phenoxy]ethoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:10260 CAPLUS
DOCUMENT NUMBER: 136:74644
TITLE: Novel process for preparing and harvesting crystalline pharmaceutical particles
INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000199	A1	20020103	WO 2001-GB2923	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294360	A1	20030326	EP 2001-943685	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500984	T2	20040115	JP 2002-504981	20010629
US 2004045805	A1	20040311	US 2003-312434	20030606
PRIORITY APPLN. INFO.:			GB 2000-16040 A	20000629
			WO 2001-GB2923 W	20010629

AB The present invention relates to a novel process for preparing and harvesting crystalline particles, particularly pharmaceutical or carrier substances of a size suitable for inhalation therapy. Fluticasone propionate was dissolved in hot acetone and then allowed to cool to ambient temperature A flow cell was then charged with a 4:1 mixture of water and acetone. Pump 1 (containing the fluticasone propionate in acetone) was set at a flow rate of 20 mL/min. Pump 2 (containing chilled water) was set at 80 mL/min. An ultrasound probe was set to deliver approx. 70-75 W of power. When the ultrasound probe and both pumps were turned on, rapid onset of crystallization occurred. The slurry output was collected in a flask and concentrated in vacuo until all of the acetone had been removed, leaving only aqueous slurry. The contents of the flask were then freeze dried overnight to give a free flowing fine dry white powder. No sieving or deaggregation of the particles by passing them through a screen was necessary.
IT 212778-82-0
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(process for preparing and harvesting crystalline pharmaceutical particles for
inhalation therapy)
RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:10259 CAPLUS
DOCUMENT NUMBER: 136:74643
TITLE: Process for preparing and harvesting crystalline pharmaceutical particles
INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000198	A1	20020103	WO 2001-GB2922	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294359	A1	20030326	EP 2001-943684	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500983	T2	20040115	JP 2002-504980	20010629
US 2003181432	A1	20030925	US 2003-312423	20030529
PRIORITY APPLN. INFO.:			GB 2000-15981 A	20000629
			WO 2001-GB2922 W	20010629

AB The present invention relates to a novel process for preparing and harvesting crystalline particles, particularly particles of pharmaceuticals or carrier substances of a size suitable for inhalation therapy. Thus, fluticasone propionate was dissolved in hot acetone and then allowed to cool to ambient temperature A flow cell then charged with a 4:1 mixture of water and acetone. Pump 1 (containing the fluticasone propionate in acetone) was set at a flow rate of 20 mL/min. Pump 2 (containing water chilled to 3-5°) was set at a flow rate of 80 mL/min. The tip of a sono-probe was positioned above the inlet of Pump 1 and set to deliver 70-75 W of power. The resultant crystalline suspension was then collected and simultaneously filtered on a filter funnel fitted with GF/C glass microfiber filter. The damp filter cake was then washed with water and then resuspended in further demineralized water to prepare a 10% weight/weight slurry. The slurry was then rapidly frozen by immersing the flask containing the slurry in a solid carbon dioxide cooling bath containing acetone, to give an even coating of ice containing particles of fluticasone propionate. The mixture was then freeze dried in vacuo for 14-18 h to give a fine white powder containing particles of inhalable quality.
IT 212778-82-0
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(process for preparing and harvesting crystalline pharmaceutical particles)
RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:859509 CAPLUS
DOCUMENT NUMBER: 136:270314
TITLE: Fluorescence properties of phenolate anions of coelenteramide analogues: the light-emitter structure in aequorin bioluminescence
AUTHOR(S): Imai, Yuko; Shibata, Takuya; Maki, Shojiro; Niwa, Haruki; Ohashi, Mamoru; Hirano, Takashi
CORPORATE SOURCE: Department of Applied Physics and Chemistry, The University of Electro-Communications, Chofu, Tokyo, 182-8585, Japan
SOURCE: Journal of Photochemistry and Photobiology, A: Chemistry (2001), 146(1-2), 95-107
CODEN: JPPCEJ; ISSN: 1010-6030
PUBLISHER: Elsevier Science S.A.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To elucidate the ionic structure of the excited state of light-emitter coelenteramide in aequorin bioluminescence, the fluorescent properties of phenolate anions of coelenteramide analogs were investigated. Fluorescence of phenolate anion in non-polar solvents was observed by electronic excitation of a 1:1 hydrogen-bonded complex of a coelenteramide analog with a hydrogen-bond donor mol. such as n-butylamine. In polar solvents, the phenolate anion was directly generated using a base, and its fluorescence was studied. These results confirm that the singlet-excited state of phenolate anion of coelenteramide has an intramol. CT character, and that its fluorescence emission wavelength changes depending upon solvent polarity. The fluoro-substituent effect on the fluorescent property of phenolate anions was also clarified to help in explaining the bioluminescent property of fluorinated semi-synthetic aequorin. These results consistently support the assignment that the phenolate anion is the ionic structure of the excited light-emitter in BFP during AQ bioluminescence.

IT **404939-52-2P 404939-55-5P**
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(fluorescence properties of phenolate anions of coelenteramide analogs and light-emitter structure in aequorin bioluminescence)

RN 404939-52-2 CAPLUS
CN Octanamide, N-[5-(2,3-difluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 404939-55-5 CAPLUS
CN Octanamide, N-[5-(2-fluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)



IT **404939-62-4 404939-66-8**
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)
(fluorescence properties of phenolate anions of coelenteramide analogs and light-emitter structure in aequorin bioluminescence in relation to)

RN 404939-62-4 CAPLUS
CN Octanamide, N-[5-(2,3-difluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]-, ion(1-) (9CI) (CA INDEX NAME)



RN 404939-66-8 CAPLUS
CN Octanamide, N-[5-(2-fluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]-, ion(1-) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:833264 CAPLUS
DOCUMENT NUMBER: 135:357945
TITLE: Two-step process for the preparation of 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine
INVENTOR(S): Edney, Dean David; Kennedy, Andrew
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085674	A1	20011115	WO 2001-GB1929	20010502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1278721	A1	20030129	EP 2001-925711	20010502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003532702	T2	20031105	JP 2001-582275	20010502
US 2003149053	A1	20030807	US 2002-275457	20021105
US 6803464	B2	20041012		
PRIORITY APPLN. INFO.:			GB 2000-10971 A	20000505
			WO 2001-GB1929 W	20010502

OTHER SOURCE(S): CASREACT 135:357945

AB A process for the preparation of 2-[[cyano(2,3,5-trichlorophenyl)methyl]amino]acetamidine or its acid-addition salts (e.g., the hydrobromide; I) comprises: (i) reaction of an acid salt of aminoacetamidine (e.g., aminoacetamidine dihydrobromide) with a source of cyanide (e.g., KCN); and (ii) reaction of the product of step (i) with 2,3,5-trichlorobenzaldehyde. 2,6-Diamino-3-(2,3,5-trichlorophenyl)pyrazine is prepared by the intramol. cyclocondensation reaction and oxidation of I or its acid-addition salts in the presence of a methanolic lithium hydroxide solution

IT **212778-82-0P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(two-step process for the preparation of 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine)

RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:617986 CAPLUS
DOCUMENT NUMBER: 135:180787
TITLE: Preparation of substituted arylpyrazines and their binding with CRF1 receptors
INVENTOR(S): Yoon, Taeyoung; Ge, Ping; Horvath, Raymond F.; De Lombaert, Stephane; Hodgetts, Kevin J.; Doller, Dario; Zhang, Cunyu
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060806	A2	20010823	WO 2001-US5264	20010216
WO 2001060806	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2398937	AA	20010823	CA 2001-2398937	20010216
EP 1255740	A2	20021113	EP 2001-910939	20010216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003018035	A1	20030123	US 2001-788315	20010216
EE 200200453	A	20031215	EE 2002-453	20010216
JP 2004500383	T2	20040108	JP 2001-560191	20010216
BR 2001008363	A	20040210	BR 2001-8363	20010216
EP 1500653	A1	20050126	EP 2004-25531	20010216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 520484	A	20050324	NZ 2001-520484	20010216
BG 106968	A	20030430	BG 2002-106968	20020731
ZA 2002006103	A	20030820	ZA 2002-6103	20020731
NO 2002003869	A	20020911	NO 2002-3869	20020815
PRIORITY APPLN. INFO.:			US 2000-182934P P	20000216
			US 2000-206455P P	20000522
			EP 2001-910939 A3	20010216
			WO 2001-US5264 W	20010216

OTHER SOURCE(S): MARPAT 135:180787
GI



AB Arylpyrazine compds. I [Ar = substituted Ph, naphthyl, heterocyclyl; R1, R3 = H, halo, cyano, NO2, etc.; R2 = halo, amino, alkyl, etc.], including arylpyrazines that can bind with high affinity and high selectivity to

102(a)

CRF1 receptors, including human CRF1 receptors, were prepared E.g., N-(1-ethylpropyl)-5-(2,4-dimethoxyphenyl)-3,6-dimethylpyrazine-2-amine was prepared by reaction of 2-chloro-3,6-dimethylpyrazine with 1-ethylpropylamine, followed by bromination and reaction with 2,4-dimethoxybenzeneboronic acid.

IT 355834-56-9P 355835-13-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted arylpyrazines and their binding with CRF1 receptors)

RN 355834-56-9 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 355835-13-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



IT 355834-36-5P 355834-37-6P 355834-38-7P
355834-40-1P 355834-41-2P 355834-44-5P
355834-45-6P 355834-46-7P 355834-48-9P
355834-49-0P 355834-50-3P 355834-52-5P
355834-53-6P 355834-54-7P 355834-57-0P
355834-58-1P 355834-59-2P 355834-60-5P
355834-61-6P 355834-62-7P 355834-63-8P
355834-64-9P 355834-65-0P 355834-66-1P
355834-67-2P 355834-68-3P 355834-69-4P
355834-70-7P 355834-71-8P 355834-72-9P
355834-73-0P 355834-74-1P 355834-75-2P
355834-76-3P 355834-77-4P 355834-78-5P
355834-79-6P 355834-84-3P 355834-85-4P
355834-86-5P 355834-87-6P 355834-88-7P
355834-89-8P 355834-90-1P 355834-91-2P
355834-92-3P 355834-93-4P 355834-94-5P
355834-95-6P 355834-96-7P 355834-97-8P
355834-98-9P 355834-99-0P 355835-00-6P
355835-01-7P 355835-02-8P 355835-03-9P
355835-04-0P 355835-05-1P 355835-06-2P
355835-07-3P 355835-08-4P 355835-09-5P
355835-10-8P 355835-11-9P 355835-12-0P
355835-14-2P 355835-15-3P 355835-16-4P
355835-17-5P 355835-18-6P 355835-19-7P
355835-20-0P 355835-21-1P 355835-22-2P
355835-23-3P 355835-24-4P 355835-25-5P
355835-26-6P 355835-27-7P 355835-30-2P
355835-31-3P 355835-33-5P 355835-35-7P
355835-37-9P 355835-38-0P 355835-39-1P
355835-40-4P 355835-41-5P 355835-42-6P
355835-43-7P 355835-44-8P 355835-45-9P
355835-46-0P 355835-47-1P 355835-48-2P
355835-49-3P 355835-50-6P 355835-51-7P
355835-52-8P 355835-53-9P 355835-54-0P
355835-55-1P 355835-56-2P 355835-57-3P
355835-58-4P 355835-59-5P 355835-60-8P
355835-61-9P 355835-62-0P 355835-63-1P
355835-64-2P 355835-66-4P 355835-70-0P
355835-71-1P 355835-72-2P 355835-73-3P
355835-74-4P 355835-75-5P 355835-76-6P
355835-77-7P 355835-78-8P 355835-79-9P
355835-80-2P 355835-81-3P 355835-82-4P
355835-83-5P 355835-84-6P 355835-85-7P
355835-86-8P 355835-87-9P 355835-88-0P
355835-89-1P 355835-90-4P 355835-91-5P
355835-92-6P 355835-93-7P 355835-94-8P
355835-95-9P 355835-96-0P 355835-97-1P
355835-98-2P 355835-99-3P 355836-00-9P
355836-02-1P 355836-03-2P 355836-04-3P
355836-39-4P 355836-41-8P 355836-42-9P
355836-46-3P 355836-47-4P 355836-48-5P
355836-50-9P 355836-52-1P 355836-54-3P
355836-56-5P 355836-57-6P 355836-58-7P
355836-59-8P 355836-60-1P 355836-61-2P
355836-62-3P 355836-63-4P 355836-64-5P
355836-65-6P 355836-66-7P 355836-67-8P
355836-68-9P 355836-69-0P 355836-70-3P
355836-71-4P 355836-72-5P 355836-73-6P
355836-74-7P 355836-75-8P 355836-76-9P
355836-77-0P 355836-78-1P 355836-80-5P
355836-81-6P 355836-82-7P 355836-83-8P
355836-84-9P 355836-85-0P 355836-86-1P
355836-87-2P 355836-88-3P 355836-89-4P
355836-90-7P 355836-91-8P 355836-92-9P
355836-93-0P 355836-94-1P 355836-95-2P
355836-96-3P 355836-97-4P 355836-98-5P
355836-99-6P 355837-00-2P 355837-01-3P
355837-03-5P 355837-04-6P 355837-06-8P
355837-07-9P 355837-08-0P 355837-09-1P
355837-10-4P 355837-12-6P 355837-14-8P
355837-23-9P 355837-24-0P 355837-25-1P
355839-94-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted arylpyrazines and their binding with CRF1 receptors)

RN 355834-36-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-37-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-38-7 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-40-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-41-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-44-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355834-45-6 CAPLUS
CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355834-46-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355834-48-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 355834-49-0 CAPLUS
CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(3-phenylpropyl)-(9CI) (CA INDEX NAME)



RN 355834-50-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-dimethyl-N-(3-phenylpropyl)-(9CI) (CA INDEX NAME)



RN 355834-52-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(1-propylbutyl)-(9CI) (CA INDEX NAME)



RN 355834-53-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(3-phenylpropyl)-(9CI) (CA INDEX NAME)



RN 355834-54-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-3,6-dimethyl-(9CI) (CA INDEX NAME)



RN 355834-57-0 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methyl-5-(2,4,6-trimethylphenyl)-(9CI) (CA INDEX NAME)



RN 355834-58-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355834-59-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-60-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355834-61-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 355834-62-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-propylbutyl)-(9CI) (CA INDEX NAME)



RN 355834-63-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-64-9 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-methylpropyl)-(9CI) (CA INDEX NAME)



RN 355834-65-0 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-phenylethyl)-(9CI) (CA INDEX NAME)



RN 355834-66-1 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-propylbutyl)-(9CI) (CA INDEX NAME)



RN 355834-67-2 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-68-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-methylpropyl)-(9CI) (CA INDEX NAME)



RN 355834-69-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355834-70-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-71-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-methylpropyl)-(9CI) (CA INDEX NAME)



RN 355834-72-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 355834-73-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 355834-74-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 355834-75-2 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355834-76-3 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-77-4 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 355834-78-5 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 355834-79-6 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 355834-84-3 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-85-4 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 355834-86-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 355834-87-6 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355834-88-7 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-89-8 CAPLUS
CN Pyrazine, 2-(1-ethylpropoxy)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-90-1 CAPLUS
CN Pyrazine, 2-(cyclopropylmethoxy)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-91-2 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-(dicyclopropylmethoxy)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-92-3 CAPLUS
CN Pyrazine, 2-(1-cyclohexylpropoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-93-4 CAPLUS
CN Pyrazine, 2-(1-cyclopentylpropoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-94-5 CAPLUS
CN Pyrazine, 2-(1-cyclopentylbutoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-95-6 CAPLUS
CN Pyrazine, 2-(cyclopropylphenylmethoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-96-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(2-propylcyclohexyl)oxy]- (9CI) (CA INDEX NAME)



RN 355834-97-0 CAPLUS
CN Pyrazine, 2-(2,4-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355834-98-9 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-99-0 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355835-00-6 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355835-01-7 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 355835-02-0 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-03-9 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 355835-04-0 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 355835-08-4 CAPLUS
CN Pyrazinamine, N-(cyclopropylmethyl)-5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-propyl- (9CI) (CA INDEX NAME)



RN 355835-09-5 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N,3,6-triethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 355835-10-8 CAPLUS
CN Pyrazinamine, 3-bromo-6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-05-1 CAPLUS
CN Pyrazinamine, N-butyl-5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N,3,6-triethyl- (9CI) (CA INDEX NAME)



RN 355835-06-2 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-07-3 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-(methoxymethyl)propyl)- (9CI) (CA INDEX NAME)



RN 355835-11-9 CAPLUS
CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 355835-12-0 CAPLUS
CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-14-2 CAPLUS
CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-15-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-fluoro- (9CI) (CA INDEX NAME)



RN 355835-16-4 CAPLUS
CN Pyrazinamine, 3-chloro-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-(9CI) (CA INDEX NAME)



RN 355835-17-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-iodo-(9CI) (CA INDEX NAME)



RN 355835-18-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy-(9CI) (CA INDEX NAME)



RN 355835-19-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methyl-(9CI) (CA INDEX NAME)



RN 355835-20-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methyl-(9CI) (CA INDEX NAME)



RN 355835-21-1 CAPLUS
CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-(9CI) (CA INDEX NAME)



RN 355835-22-2 CAPLUS
CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy-(9CI) (CA INDEX NAME)



RN 355835-23-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl-(9CI) (CA INDEX NAME)



RN 355835-24-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl-(9CI) (CA INDEX NAME)



RN 355835-25-5 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 355835-26-6 CAPLUS
CN Pyrazine, 2-ethyl-3-(1-ethylpropoxy)-5-methoxy-6-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355835-27-7 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-(methylthio)- (9CI) (CA INDEX NAME)



RN 355835-30-2 CAPLUS
CN 1-Butanol, 2-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]amino]- (9CI) (CA INDEX NAME)



RN 355835-31-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355835-33-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 355835-35-7 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-methylphenyl)-(9CI) (CA INDEX NAME)



RN 355835-37-9 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)-(9CI) (CA INDEX NAME)



RN 355835-38-0 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)-(9CI) (CA INDEX NAME)



RN 355835-39-1 CAPLUS
CN 2(1H)-Pyridinone, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-methoxy- (9CI) (CA INDEX NAME)



RN 355835-40-4 CAPLUS
CN 2(1H)-Pyridinone, 3-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-methoxy- (9CI) (CA INDEX NAME)



RN 355835-41-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 355835-42-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 355835-43-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 355835-44-8 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 355835-45-9 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methylphenyl)-(9CI) (CA INDEX NAME)



RN 355835-46-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N,N-bis(2-methoxyethyl)-(9CI) (CA INDEX NAME)



RN 355835-47-1 CAPLUS
CN Pyrazinamine, N-(cyclopropylmethyl)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-propyl- (9CI) (CA INDEX NAME)



RN 355835-48-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxy-5-pyrimidinyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-49-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4,6-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 355835-50-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(dicyclopropylmethyl)-3,6-diethyl-(9CI) (CA INDEX NAME)



RN 355835-51-7 CAPLUS
CN 1,2-Propanediamine, N2-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)



RN 355835-52-8 CAPLUS
CN Pyrazinamine, N-(dicyclopropylmethyl)-5-(2,4-dimethoxyphenyl)-3,6-diethyl-(9CI) (CA INDEX NAME)



RN 355835-53-9 CAPLUS
CN Pyrazinamine, 5-(2,6-dimethoxy-3-pyridinyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-54-0 CAPLUS
CN Pyrazinamine, N-(dicyclopropylmethyl)-5-(2,6-dimethoxy-3-pyridinyl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 355835-55-1 CAPLUS
CN 1,2-Ethanediamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N',N'-dimethyl-N-propyl- (9CI) (CA INDEX NAME)



RN 355835-56-2 CAPLUS
CN Pyrazinamine, 5-(2,4-diethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-57-3 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methoxy- (9CI) (CA INDEX NAME)



RN 355835-58-4 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-ethoxy- (9CI) (CA INDEX NAME)



RN 355835-59-5 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 355835-60-8 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-(difluoromethoxy)- (9CI) (CA INDEX NAME)



RN 355835-61-9 CAPLUS
CN Phenol, 4-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 355835-62-0 CAPLUS
CN Pyrazinamine, 5-(4-ethoxy-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-63-1 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355835-64-2 CAPLUS
CN Pyrazinamine, 5-[2,4-bis(1-methylethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-66-4 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 355835-70-0 CAPLUS
CN Pyrazinamine, 5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-71-1 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 355835-72-2 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-[2-methoxy-1-(methoxymethyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 355835-73-3 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355835-74-4 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 355835-75-5 CAPLUS
CN Pyrazine, 2-(1-cyclohexylbutoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355835-76-6 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-[(4-methoxycyclohexyl)oxy]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355835-77-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(tetrahydro-3-furanyl)oxy]- (9CI) (CA INDEX NAME)



RN 355835-78-8 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 355835-79-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(1-methyl-3-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 355835-80-2 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-[(1-ethyl-3-piperidinyl)oxy]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355835-81-3 CAPLUS
CN Cyclohexanamine, 4-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 355835-82-4 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(4-piperidinyloxy)- (9CI) (CA INDEX NAME)



RN 355835-83-5 CAPLUS
CN 1-Propanamine, 2-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]oxy]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 355835-84-6 CAPLUS
CN 1-Butanamine, 2-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]oxy]- (9CI) (CA INDEX NAME)



RN 355835-85-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(3-piperidinyloxy)- (9CI) (CA INDEX NAME)



RN 355835-86-8 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-[(1-ethyl-3-pyrrolidinyl)oxy]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355835-87-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(1-methyl-3-pyrrolidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 355835-88-0 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(3-pyrrolidinyloxy)- (9CI) (CA INDEX NAME)



RN 355835-89-1 CAPLUS
CN Butanoic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 355835-90-4 CAPLUS
CN Pentanoic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 355835-95-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355835-96-0 CAPLUS
CN Morpholine, 4-(2-[2-[3,6-diethyl-5-(1-ethylpropoxy)pyrazinyl]-3,5-dimethylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 355835-97-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethoxy-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-98-2 CAPLUS



RN 355835-91-5 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(4-pyridinyloxy)- (9CI) (CA INDEX NAME)



RN 355835-92-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 355835-93-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-(1-ethylpropoxy)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355835-94-8 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-(1-ethylpropoxy)pyrazinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 355835-99-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355836-00-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355836-02-1 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-03-2 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-04-3 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trichlorophenyl)-(9CI) (CA INDEX NAME)



RN 355836-39-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy-(9CI) (CA INDEX NAME)



RN 355836-41-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 355836-42-9 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 355836-52-1 CAPLUS
CN Pyrazine, 2,5-diethyl-3-[2-methyl-1-(1-methylethyl)propoxy]-6-[2-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-54-3 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-56-5 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-57-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy-(9CI) (CA INDEX NAME)



RN 355836-46-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 355836-47-4 CAPLUS
CN Pyrazinamine, 5-(2,6-dichloro-4-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355836-48-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(3-methyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)



RN 355836-50-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1-methylbutoxy)- (9CI) (CA INDEX NAME)



RN 355836-58-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-59-8 CAPLUS
CN Carbonodithioic acid, O-[3-chloro-4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazinyl]phenyl] S-propyl ester (9CI) (CA INDEX NAME)



RN 355836-60-1 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-[2-methoxy-4,6-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-61-2 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 355836-62-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355836-63-4 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355836-64-5 CAPLUS
CN Carbonodithioic acid, O-[3-chloro-4-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]phenyl] S-propyl ester (9CI) (CA INDEX NAME)



RN 355836-65-6 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2,6-dimethoxyphenyl)-3-ethoxy-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-66-7 CAPLUS
CN Pyrazine, 2-(2,4-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)



RN 355836-67-8 CAPLUS
CN Pyrazinamine, 5-[4-(1,3-dioxolan-2-yl)-2,6-dimethoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-68-9 CAPLUS
CN Pyrazinamine, 5-(4-ethoxy-2,6-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355836-69-0 CAPLUS
CN Pyrazinamine, 5-(2,6-dimethoxy-4-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 355836-70-3 CAPLUS
CN Pyrazine, 2-(2-chloro-4-methoxyphenyl)-3,6-diethyl-5-[2-methyl-1-(1-methylethyl)propoxy]- (9CI) (CA INDEX NAME)



RN 355836-71-4 CAPLUS
CN Benzenemethanol, 4-[3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxypyrazinyl]-3,5-dimethoxy-α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 355836-72-5 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-73-6 CAPLUS
CN Pyrazinamine, 3-ethyl-5-(2-ethyl-4-methoxyphenyl)-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355836-74-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355836-75-8 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(1-methylethoxy)phenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355836-76-9 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 355836-77-0 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-78-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 355836-80-5 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 355836-81-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 355836-82-7 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(2-ethyl-4-methoxyphenyl)-6-(1-propylbutoxy)- (9CI) (CA INDEX NAME)



RN 355836-83-8 CAPLUS
CN Pyrazinamine, 5-[4-ethoxy-2-(1-methylethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-84-9 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355836-85-0 CAPLUS
CN Pyrazine, 2-[2-chloro-4-(trifluoromethyl)phenyl]-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)



RN 355836-86-1 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-[4-(1-fluoroethyl)-2,6-dimethoxyphenyl]-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-87-2 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(2-methoxyethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-88-3 CAPLUS
CN Pyrazinamine, 5-[4-(difluoromethoxy)-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-89-4 CAPLUS
CN Pyrazinamine, 5-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-90-7 CAPLUS
CN Benzenemethanol, 4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 355836-91-8 CAPLUS
CN Pyrazinamine, 5-[4-(difluoromethoxy)-2-methoxyphenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355836-92-9 CAPLUS
CN Pyrazine, 2-(2-chloro-4-propoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355836-93-0 CAPLUS
CN Pyrazine, 2-(2-chloro-4-(cyclopropylmethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355836-94-1 CAPLUS
CN Pyrazine, 2-[2-chloro-4-(2-fluoroethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355836-95-2 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(1-methylethoxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-96-3 CAPLUS
CN Pyrazine, 2-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(1-methylethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355836-97-4 CAPLUS
CN Pyrazine, 2-(4-ethoxy-2-methoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355836-98-5 CAPLUS
CN Pyrazine, 2-(2,6-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355837-04-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 355837-06-8 CAPLUS
CN Pyrazinamine, 6-chloro-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355837-07-9 CAPLUS
CN Pyrazine, 2-(4-butoxy-2-chlorophenyl)-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)



RN 355837-08-0 CAPLUS
CN Pyrazinamine, N-(1-ethylbutyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-99-6 CAPLUS
CN Phenol, 4-[3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxypyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 355837-00-2 CAPLUS
CN Pyrazinamine, 6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355837-01-3 CAPLUS
CN Phenol, 4-[3,6-diethyl-5-[2-methyl-1-(1-methylethyl)propoxy]pyrazinyl]-3-ethyl- (9CI) (CA INDEX NAME)



RN 355837-03-5 CAPLUS
CN Pyrazine, 2,5-diethyl-3-[2-methyl-1-(1-methylethyl)propoxy]-6-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 355837-09-1 CAPLUS
CN Pyrazine, 2-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-ethoxyphenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)



RN 355837-10-4 CAPLUS
CN Formamide, N-[6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazinyl]- (9CI) (CA INDEX NAME)



RN 355837-12-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-[2-(1-methylethoxy)-4-propoxyphenyl]- (9CI) (CA INDEX NAME)



RN 355837-14-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2,6-dimethoxyphenyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355837-23-9 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 355837-24-0 CAPLUS
CN Pyrazine, 2-(4-chloro-2,6-dimethoxyphenyl)-3-ethyl-5-(1-ethylpropoxy)-6-methoxy- (9CI) (CA INDEX NAME)



RN 355837-25-1 CAPLUS
CN Pyrazinamine, 5-ethyl-3-(1-ethylpropoxy)-6-[2-methoxy-5-(trifluoromethoxy)phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 355839-94-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)

(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-28-1 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-, 4-oxide (9CI) (CA INDEX NAME)



RN 355836-29-2 CAPLUS
CN Pyrazinamine, 6-chloro-3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-34-9 CAPLUS
CN Pyrazinamine, 6-methoxy-N-[(4-methoxyphenyl)methyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-35-0 CAPLUS
CN Pyrazinamine, 3-bromo-6-methoxy-N-[(4-methoxyphenyl)methyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



IT 355836-12-3P 355836-19-0P 355836-20-3P
355836-27-0P 355836-28-1P 355836-29-2P
355836-34-9P 355836-35-0P 355836-36-1P
355836-37-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted arylpyrazines and their binding with CRF1 receptors)

RN 355836-12-3 CAPLUS
CN 2(1H)-Pyridinone, 3-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-hydroxy- (9CI) (CA INDEX NAME)



RN 355836-19-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-20-3 CAPLUS
CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 355836-27-0 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-



RN 355836-36-1 CAPLUS
CN Pyrazinamine, 3-ethyl-6-methoxy-N-[(4-methoxyphenyl)methyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-37-2 CAPLUS
CN Pyrazinamine, 3-ethyl-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



LS ANSWER 27 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:472472 CAPLUS
DOCUMENT NUMBER: 135:81972
TITLE: Formulations of adenosine A1 agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045684	A2	20010628	WO 2000-GB4888	20001219
WO 2001045684	A3	20020314		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1239880 A2 20020918 EP 2000-985631 20001219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003518042 T2 20030603 JP 2001-546423 20001219
US 2003008862 A1 20030109 US 2002-168196 20020618
PRIORITY APPLN. INFO.: GB 1999-30079 A 19991220
WO 2000-GB4888 W 20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and a sodium channel blocker. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection.

IT **212778-82-0 259828-60-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulations of adenosine A1 agonists)

RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 259828-60-9 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



LS ANSWER 28 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:314448 CAPLUS
DOCUMENT NUMBER: 135:118864
TITLE: Catechol derivatives of aminopyrazine and cell protection against uvb-induced mortality
AUTHOR(S): Cavalier, J.-F.; Burton, M.; Dussart, F.; Marchand, C.; Rees, J.-F.; Marchand-Brynaert, J.
CORPORATE SOURCE: Unite de Chimie Organique et Medicinale, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(4), 1037-1044
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of 5-aryl- and 3,5-bis-aryl-2-amino-1,4-pyrazine derivs. and related imidazolopyrazinones has been synthesized, the aryl groups of which are catechol and/or phenol substituents. These compds., tested against human keratinocyte cells stressed by UVB irradiation, showed high antioxidative properties. One compound was more active than EGCG/ECG (green tea extract) in reducing cell mortality.

IT **350819-15-7P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(catechol derivs. of aminopyrazine and cell protection against UVB)

RN 350819-15-7 CAPLUS
CN 1,3-Benzenediol, 4-(5-aminopyrazinyl)- (9CI) (CA INDEX NAME)



IT **154616-04-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(catechol derivs. of aminopyrazine and cell protection against UVB)

RN 154616-04-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 29 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:78356 CAPLUS
DOCUMENT NUMBER: 134:131548
TITLE: Preparation of tricyclic compounds as allergy inhibitors, immunosuppressants, and IgE production inhibitors
INVENTOR(S): Tanimoto, Norihiko; Inagaki, Masanao
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007401	A1	20010201	WO 2000-JP4726	20000714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000060160	A5	20010213	AU 2000-60160	20000714
PRIORITY APPLN. INFO.:			JP 1999-209298	A 19990723
			JP 1999-211702	A 19990727
			WO 2000-JP4726	W 20000714

OTHER SOURCE(S): MARPAT 134:131548
GI



AB The title compds. I [A, B and C are each an aromatic carbo- or hetero-cycle or the like, with the proviso that when A is an optionally substituted five-membered heterocycle, W1 is a bond, the same applying in the case of B and W2 and that of C and W3; X and X' are each O, NH, or the like; Y is lower alkyl, lower alkenyl, or the like; V1 and V2 are each a single bond or the like; Ra and Rb are each hydrogen, lower alkyl, lower alkenyl, or the like; further details on Ra and Rb are given ; n is 0 to 2] are prepared Several compds. of this invention at 40 mg/kg/day orally for 10 days suppressed the production of IgE in a mouse model. Formulations are given.

IT **321982-04-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic compds. as allergy inhibitors, immunosuppressants, and IgE production inhibitors)

RN 321982-04-1 CAPLUS
CN 2-Propenone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[[3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]pyrazinyl]oxime (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 30 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:456951 CAPLUS
DOCUMENT NUMBER: 133:79433
TITLE: Apparatus and process for preparing crystalline particles
INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038811	A1	20000706	WO 1999-GB4368	19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6482438	B1	20021119	US 1999-348948	19990707
CA 2356897	AA	20000706	CA 1999-2356897	19991222
BR 9916587	A	20010925	BR 1999-16587	19991222
EP 1144065	A1	20011017	EP 1999-962413	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
TR 200101845	T2	20011022	TR 2001-200101845	19991222
JP 2002533205	T2	20021008	JP 2000-590755	19991222
JP 3588050	B2	20041110		
NZ 512400	A	20030228	NZ 1999-512400	19991222
AU 759880	B2	20030501	AU 2000-18771	19991222
NO 2001003039	A	20010822	NO 2001-3039	20010619
ZA 2001005070	A	20020920	ZA 2001-5070	20010620
PRIORITY APPLN. INFO.:			GB 1998-28721	A 19981224
			WO 1999-GB4368	W 19991222

AB A process for preparing crystalline particles, especially particles of a pharmaceutical
or carrier substance suitable for inhalation therapy is described, in addition to an apparatus for the preparation of such particles. An example is give for
distribution of particles of crystalline fluticasone propionate.

IT **212778-82-0**
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(apparatus and process for preparing crystalline particles)

RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:335409 CAPLUS
DOCUMENT NUMBER: 132:334474
TITLE: Preparation of spiroindolines as Y5 receptor antagonists
INVENTOR(S): Gao, Ying-duo; Macneil, Douglas J.; Yang, Lihu; Morin, Nancy R.; Fukami, Takehiro; Kanatani, Akio; Fukuroda, Takahiro; Ishii, Yasuyuki; Morin, Masaki
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.; et al.
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027845	A1	20000518	WO 1999-US26447	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2350714	AA	20000518	CA 1999-2350714	19991108
US 6191160	B1	20010220	US 1999-436120	19991108
EP 1129089	A1	20010905	EP 1999-971808	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 756797	B2	20030123	AU 2000-14732	19991108
US 6313298	B1	20011106	US 2000-656698	20000907
US 2002058813	A1	20020516	US 2001-896940	20010629
US 6495559	B2	20021217		
US 6638942	B1	20031028	US 2002-228250	20020826
US 2004063942	A1	20040401	US 2003-624414	20030721

PRIORITY APPLN. INFO.:
US 1998-107835P P 19981110
US 1999-436120 A3 19991108
WO 1999-US26447 W 19991108
US 2000-656698 A3 20000907
US 2001-896940 A3 20010629
US 2002-228250 A3 20020826

OTHER SOURCE(S): MARPAT 132:334474
GI



AB The title compds. I [V, W, X, Z = CH, N; R1 = H, alkyl, etc.; R2 = CHO, etc.; R3 = H, alkyl; Ar = aryl, heteroaryl; R4, R5 = H, nitro, etc.] are prepared I are useful in the treatment of obesity and the complications associated therewith. 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide at 3 mg/kg suppressed bovine pancreatic polypeptide-induced food intake in rats. Formulations are given.

IT 268536-93-2P 268536-94-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiroindolines as Y5 receptor antagonists)

RN 268536-93-2 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, 1,2-dihydro-N-[5-(2-methoxyphenyl)pyrazinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 268536-94-3 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-[5-(2-chlorophenyl)pyrazinyl]-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:161266 CAPLUS
DOCUMENT NUMBER: 132:194395
TITLE: Preparation of pyrazines as anticonvulsants
INVENTOR(S): Cox, Brian; Healy, Mark Patrick; Wild, Deborah
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012488	A1	20000309	WO 1999-EP6248	19990826
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2341543	AA	20000309	CA 1999-2341543	19990826
AU 9956249	A1	20000321	AU 1999-56249	19990826
BR 9913183	A	20010515	BR 1999-13183	19990826
EP 1107960	A1	20010620	EP 1999-942919	19990826
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100603	T2	20010723	TR 2001-200100603	19990826
JP 2002523499	T2	20020730	JP 2000-567518	19990826
TW 429255	B	20010411	TW 1999-88114723	19990827
US 6503909	B1	20030107	US 2001-762295	20010208
US 2003022904	A1	20030130	US 2002-216399	20020812

PRIORITY APPLN. INFO.:
GB 1998-18881 A 19980828
WO 1999-EP6248 W 19990826
US 2001-762295 A1 20010208

OTHER SOURCE(S): MARPAT 132:194395
GI



AB The title compds. [I; R1 = Ph substituted by one or more halogen atoms; R2 = NH2; R3 = NH2, H; R4 = CXNRaRb, CXNH(CH2)yNRaRb (wherein X = O, S; y = 0-2; Ra, Rb = H, alkyl; NRaRb = (un)substituted saturated 5-6 membered heterocycle containing one or two N atoms)], useful in the treatment of CNS diseases such as epilepsy, were prepared and formulated. E.g., a multi-step synthesis of pyrazine I [R1 = 2,3,5-Cl3C6H2; R2 = R3 = NH2; R4 = CONH2] was given. Compds. I showed ED50 of 1.4 mg/kg compared to 6.1 mg/kg for lamotrigine with a therapeutic index (ratio of the ataxia ED50 and MES ED50) of 21.6 compared to 3.3 for lamotrigine.

IT 259828-60-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazines as anticonvulsants)

RN 259828-60-9 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



IT 259828-61-0P 259828-62-1P 259828-63-2P
259828-65-4P 259828-67-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazines as anticonvulsants)
RN 259828-61-0 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N-methyl-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 259828-62-1 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N-ethyl-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 259828-63-2 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N-(1-methylethyl)-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-13-0 CAPLUS
CN Pyrazinecarbonitrile, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-41-6 CAPLUS
CN 2,6-Pyrazinediamine, 3-bromo-5-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:495258 CAPLUS
DOCUMENT NUMBER: 131:129907
TITLE: Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors
INVENTOR(S): Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiro
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938829	A1	19990805	WO 1999-JP297	19990126
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,				



RN 259828-65-4 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N,N-dimethyl-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 259828-67-6 CAPLUS
CN Pyrazinecarbothioamide, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



IT 212778-82-0P 212779-13-0P 212779-41-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazines as anticonvulsants)
RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)

MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2318368	AA	19990805	CA 1999-2318368	19990126
AU 9919837	A1	19990816	AU 1999-19837	19990126
AU 742641	B2	20020110		
EP 1052238	A1	20001115	EP 1999-900676	19990126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9908539	A	20001205	BR 1999-8539	19990126
TR 200002225	T2	20001221	TR 2000-200002225	19990126
NZ 506101	A	20030630	NZ 1999-506101	19990126
RU 2216533	C2	20031120	RU 2000-121556	19990126
NO 2000003706	A	20000914	NO 2000-3706	20000719
US 6562817	B1	20030513	US 2000-600790	20000721
PRIORITY APPLN. INFO.:			JP 1998-15554 A	19980128
			WO 1999-JP297 W	19990126

OTHER SOURCE(S): MARPAT 131:129907
GI



I



II

AB The title compds. I [each of ring A, ring B and ring C is independently a substituted or unsubstituted aromatic ring or a substituted or unsubstituted five or six-membered heterocycle which may be condensed with a benzene ring; when ring A, ring B and/or ring C is a substituted or unsubstituted five-membered heterocycle, W1, W2 and/or W3 represents a bond; X is O or NR1 (where R1 is hydrogen, a lower alkyl or the like); Y is hydrogen, a lower alkyl, a lower alkenyl or the like ; one of V1 and V2 is a single bond and the other is a single bond, O, etc.] are prepared The title compound II in vitro showed IC50 of 400 ng/mL against the growth of mouse EL4 cells. The inhibiting activities of compds. of this invention against the production of IgE were also demonstrated.
IT 234428-40-1P 234428-41-2P 234428-42-3P
234428-43-4P 234428-44-5P 234428-45-6P
234428-46-7P 234428-47-8P 234428-48-9P
234428-49-0P 234428-50-3P 234428-51-4P
234428-52-5P 234428-53-6P 234428-60-5P
234429-20-0P 234429-21-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic compds. as immunosuppressants and allergy inhibitors)

RN 234428-40-1 CAPLUS
CN Pyrazinamine, 5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-41-2 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-42-3 CAPLUS
CN Pyrazinamine, N-cyclohexyl-5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-43-4 CAPLUS
CN Pyrazinamine, N-cyclohexyl-5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-44-5 CAPLUS

CN Pyrazinamine, 5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234428-45-6 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234428-46-7 CAPLUS
CN Pyrazinamine, 5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234428-47-8 CAPLUS
CN Pyrazinamine, 5-[4'-[bis(3-methylbutyl)amino]-2,5-dimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234428-48-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4'-[5-[(3-methyl-2-butenyl)oxy]pyrazinyl]- (9CI) (CA INDEX NAME)



RN 234428-49-0 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-50-3 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234428-51-4 CAPLUS
CN Pyrazinamine, 5-(4'-amino-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl)-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234428-52-5 CAPLUS
CN Pyrazinamine, N-(3-methyl-2-butenyl)-5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-53-6 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234428-60-5 CAPLUS
CN 2(1H)-Pyrazinone, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234429-20-0 CAPLUS
CN Pyrazinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 234429-21-1 CAPLUS
CN Pyrazinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]phenyl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:608606 CAPLUS
DOCUMENT NUMBER: 129:230741
TITLE: Preparation of pyrazines as anticonvulsants
INVENTOR(S): Cox, Brian; Nobbs, Malcolm Stuart; Shah, Gita Punjabhai; Edney, Dean David; Loft, Michael Simon
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9838174	A1	19980903	WO 1998-EP1077	19980226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2282585	AA	19980903	CA 1998-2282585	19980226
AU 9868237	A1	19980918	AU 1998-68237	19980226
AU 732915	B2	20010503		
ZA 9801624	A	19990826	ZA 1998-1624	.19980226
EP 966448	A1	19991229	EP 1998-913592	19980226
EP 966448	B1	20031001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9807814	A	20000222	BR 1998-7814	19980226
EE 9900376	A	20000417	EE 1999-376	19980226
TR 9902082	T2	20000421	TR 1999-9902082	19980226
JP 2000511203	T2	20000829	JP 1998-537310	19980226
JP 3369189	B2	20030120		
NZ 337121	A	20010330	NZ 1998-337121	19980226
JP 2002308773	A2	20021023	JP 2002-47974	19980226
CN 1105111	B	20030409	CN 1998-804593	19980226
IL 131293	A1	20030731	IL 1998-131293	19980226
AT 251143	E	20031015	AT 1998-913592	19980226
PT 966448	T	20040227	PT 1998-913592	19980226
ES 2205469	T3	20040501	ES 1998-913592	19980226
TW 513416	B	20021211	TW 1998-87103079	19980303
US 6255307	B1	20010703	US 1999-380062	19990825
MX 9907910	A	20000228	MX 1999-7910	19990826
NO 9904213	A	19991029	NO 1999-4213	19990831
NO 313383	B1	20020923		
BG 103723	A	20010531	BG 1999-103723	19990909
HK 1023116	A1	20040116	HK 2000-102173	20000410
US 2002169172	A1	20021114	US 2001-855703	20010516
US 6599905	B2	20030729		

PRIORITY APPLN. INFO.:

GB 1997-4275	A	19970301
GB 1997-8183	A	19970423
JP 1998-537310	A3	19980226
WO 1998-EP1077	W	19980226
US 1999-380062	A3	19990825

OTHER SOURCE(S): MARPAT 129:230741
GI



I

AB The title compds. [I; R1 (un)substituted by one or more halo atoms Ph, naphthyl; R2 = NH2, NHC(O)Ra; R3 = NRbRc, NHC(O)Ra, H; R4 = H, (un)substituted by one or more halo atoms C1-4 alkyl, CN, etc.; Ra = C1-4 alkyl, C3-7 cycloalkyl; Rb, Rc = H, C1-4 alkyl; NRbRc = (un)substituted 6-membered nitrogen containing heterocycle; with the proviso that R1 does not represent 4-ClC6H4 when R2 = NH2, and R3, R4 = H], useful in the treatment of epilepsy, bipolar disorder or manic depression, pain, functional bowel disorders, neurodegenerative diseases, neuroprotection, neurodegeneration, or prevention or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence-inducing agent, were prepared and formulated. Thus, treatment of 2-amino-6-chloro-3-(2,3,5-trichlorophenyl)pyrazine (preparation described) with aqueous ammonia in EtOH afforded 56% I (R1 = 2,3,5-Cl3C6H2; R2 = R3 = NH2; R4 = H). Compds. I exhibited ED50's of 1-20 mg/kg when tested for antiepileptic activity.

IT 212778-82-0P 212778-83-1P 212779-15-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazines as anticonvulsants)

RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212778-83-1 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-15-2 CAPLUS
CN Pyrazinemethanol, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



IT 212778-84-2P 212778-96-6P 212779-00-5P
212779-01-6P 212779-03-8P 212779-05-0P
212779-07-2P 212779-09-4P 212779-13-0P
212779-17-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazines as anticonvulsants)

RN 212778-84-2 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212778-96-6 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3-dichlorophenyl)-N6,N6-dimethyl- (9CI) (CA INDEX NAME)



RN 212779-00-5 CAPLUS
CN Cyclopropanecarboxamide, N,N'-[3-(2,3,5-trichlorophenyl)-2,6-pyrazinediyl]bis- (9CI) (CA INDEX NAME)



RN 212779-01-6 CAPLUS
CN Cyclopropanecarboxamide, N-[6-amino-5-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 212779-03-8 CAPLUS
CN Propanamide, N,N'-[3-(2,3,5-trichlorophenyl)-2,6-pyrazinediyl]bis[2-methyl- (9CI) (CA INDEX NAME)



RN 212779-05-0 CAPLUS
CN Propanamide, N-[6-amino-5-(2,3,5-trichlorophenyl)pyrazinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 212779-07-2 CAPLUS
CN Propanamide, N-[6-amino-3-(2,3,5-trichlorophenyl)pyrazinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 212779-09-4 CAPLUS
CN Cyclopropanecarboxamide, N-[6-amino-3-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 212779-13-0 CAPLUS
CN Pyrazinecarbonitrile, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-17-4 CAPLUS
CN 2,6-Pyrazinediamine, 3-methyl-5-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



IT 212779-29-8P 212779-35-6P 212779-38-9P
212779-39-0P 212779-41-4P 212779-42-5P
212779-43-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazines as anticonvulsants)

RN 212779-29-8 CAPLUS
CN Acetamide, N-[6-amino-5-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 212779-35-6 CAPLUS
CN Acetamide, N-[6-amino-5-(2,5-dichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 212779-38-9 CAPLUS
CN Propanamide, N-[6-(acetylamino)-3-(2,3,5-trichlorophenyl)pyrazinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 212779-39-0 CAPLUS
CN Cyclopropanecarboxamide, N-[6-(acetylamino)-3-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 212779-41-4 CAPLUS
CN 2,6-Pyrazinediamine, 3-bromo-5-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-42-5 CAPLUS
CN Pyrazinecarboxaldehyde, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-43-6 CAPLUS
CN Benzenesulfonic acid, 4-methyl-, [[3,5-diamino-6-(2,3,5-trichlorophenyl)pyrazinyl]methylene]hydrazide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:482779 CAPLUS
DOCUMENT NUMBER: 129:227130
TITLE: Bioluminescent properties of fluorinated semi-synthetic aequorins
AUTHOR(S): Hirano, Takashi; Ohmiya, Yoshihiro; Maki, Shojiro; Niwa, Haruki; Ohashi, Mamoru
CORPORATE SOURCE: Department of Applied Physics and Chemistry, The University of Electro-Communications, Tokyo, 182, Japan
SOURCE: Tetrahedron Letters (1998), 39(31), 5541-5544
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Bioluminescent properties of semi-synthetic aequorins containing coelenterazine analogs I (X, Y = H, F) possessing fluoro group(s) on the 6-(4-hydroxyphenyl) group match the fluorescent behavior of the phenolate anions of the corresponding fluorinated coelenteramide analogs II. This indicates that the phenolate anion of coelenteramide is the light-emitter in aequorin bioluminescence.

IT 212842-96-1P
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation and bioluminescent properties of fluorinated semi-synthetic aequorins)

RN 212842-96-1 CAPLUS
CN Benzeneacetamide, N-[5-(2,3-difluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]-4-hydroxy- (9CI) (CA INDEX NAME)



IT 212842-99-4P 212843-01-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bioluminescent properties of fluorinated semi-synthetic aequorins)
RN 212842-99-4 CAPLUS
CN Pyrazinamine, 5-[2,3-difluoro-4-(phenylmethoxy)phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 212843-01-1 CAPLUS
CN Phenol, 4-[5-amino-6-(phenylmethyl)pyrazinyl]-2,3-difluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:613880 CAPLUS
DOCUMENT NUMBER: 127:293247
TITLE: Preparation of pyrrolopyrazines as GABAa receptor ligands
INVENTOR(S): Blum, Charles; Hutchison, Alan
PATENT ASSIGNEE(S): Neurogen Corp., USA
SOURCE: U.S., 16 pp., Cont.-in-part of U.S. 5,606,059.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5668283	A	19970916	US 1995-486595	19950607
US 5286860	A	19940215	US 1992-975409	19921112
US 5606059	A	19970225	US 1995-436252	19950512
US 5910590	A	19990608	US 1997-931648	19970916
PRIORITY APPLN. INFO.:			US 1992-975409	A2 19921112
			US 1995-436252	A2 19950512
			WO 1993-US10870	W 19931110
			US 1995-486595	A1 19950607

OTHER SOURCE(S): MARPAT 127:293247
GI



AB Fluorescent 2,3-cyanobenzofuro[2,3-b]pyrazine derivs. [I; Y, Z = H, lower alkyl, lower alkoxy, di(lower alkyl)amino; provided that at least one of Y and Z = di(lower alkyl)amino] are prepared by cyclocondensation of 2,3-dihalo-5,6-dicyanopyrazins (II; X = halo) with phenol derivs. [III; R = H, HO-protecting group; A, B = H, lower alkyl, lower alkoxy, di(lower alkyl)amino] under heating in solvent followed by treatment with an alkali or acid. Thus, 398 mg 2,3-dichloro-5,6-dicyanopyrazine was dissolved in 50 mL toluene, followed by adding dropwise a solution of 274 mg 3-dimethylaminophenol in 5 mL toluene, and the resulting mixture was refluxed for 24 h to give, after workup and alumina column chromatog., 306 mg I (Y = H, Z = NMe2). The latter compound showed the maximum absorbency at 430 nm and the maximum fluorescence at 528 nm. in EtOH.
IT 173339-00-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dicyanobenzofuro[2,3-b]pyrazine derivs. as fluorescent substances)
RN 173339-00-9 CAPLUS
CN Pyrazinecarbonitrile, 5-chloro-6-[2-(dimethylamino)-6-hydroxyphenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:541426 CAPLUS
DOCUMENT NUMBER: 122:290892
TITLE: Preparation of diphenylpyrazine derivatives as herbicides
INVENTOR(S): Yanai, Toshiaki; Tsukamoto, Yoshihisa; Sakamoto, Takashi; Teramura, Masahiro; Pponma, Toyokuni
PATENT ASSIGNEE(S): Sankyo Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07033752	A2	19950203	JP 1993-176525	19930716



AB Title compds. [I; R = (un)substituted Ph, -thienyl, -pyridyl; R4R5 = (CH2)nCR1R2ZCH2 or CH:CR6Z1:Z2; R1,R2,R6 = H or alkyl; Z = NR3, CO, CH(OH), alkoxycarbonylmethine, etc.; R3 = H, (phenyl)alkyl, Ph, alkoxy, etc.; Z1 = NCR15; R15 = H, halo, (phenyl)alkyl, etc.; Z2 = CH or N; n = 0-2] were prepared Thus, 2,5-F(MeO)C6H3COCHO was cyclocondensed with H2NCH2CONH2 and the product converted in 4 steps to I [R = C6H4(OMe)F-5,2, R4R5 = (CH2)4]. Data for biol. activity of I were given.
IT 154032-60-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolopyrazines as GABAa receptor ligands)
RN 154032-60-7 CAPLUS
CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)-, hydrazone (9CI) (CA INDEX NAME)



L5 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:99369 CAPLUS
DOCUMENT NUMBER: 124:146199
TITLE: Preparation of 2,3-dicyanobenzofuro[2,3-b]pyrazine derivatives as fluorescent substances
INVENTOR(S): Matsuoka, Masaru; Matsushima, Yoshimasa
PATENT ASSIGNEE(S): Takasago Perfumery Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07247288	A2	19950926	JP 1994-65424	19940310
PRIORITY APPLN. INFO.:			JP 1994-65424	19940310

OTHER SOURCE(S): CASREACT 124:146199; MARPAT 124:146199
GI



AB The title compds. [I; R1 = H, alkyl, alkoxycarbonylmethyl; R2 = alkyl optionally halogenated by 1-3 halogen atoms, alkoxy, alkenyloxy, OH, cyclohexyloxy, PhO, pyridyloxy, cyanomethoxy, (un)substituted NH2; R3 = H, alkyl, NO2, NH2, cyano, halo, PhCO, CH2Ph, alkoxycarbonyl, alkoxycarbonylmethoxy; R4, R5 = H, halo, alkyl, alkoxy; A = O, S(O)n (wherein n = 0,1,2), NHNH, NH, NMe; m = 0,1], which show excellent herbicidal activity for weeds of rice paddy such Echinochloa crus-galli, broad leaf weeds, and Scirpus juncoides, are prepared A herbicide composition contains I as the active ingredient. Thus, 2-hydroxy-5,6-diphenylpyrazine was slowly added dropwise to a suspension of NaH in DMF under ice-cooling followed by adding Et bromoacetate dropwise and the resulting mixture was stirred at room temperature for 1.5 h to give 100% Et (5,6-diphenyl-2-pyrazinyloxy)acetate (II). II at 50 g/are inhibited the growth of E. crus-galli, broad leaf weed, Eleocharis acicularis, Cyperus serotinus, Eleocharis kuroguwai, and S. juncoides by 91-100% in potted paddy soil, whereas rice seedlings were not damaged.
IT 162928-08-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diphenylpyrazine derivs. as herbicides)
RN 162928-08-7 CAPLUS
CN Acetic acid, [(5,6-bis(2-chlorophenyl)pyrazinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:508837 CAPLUS
DOCUMENT NUMBER: 121:108837
TITLE: Liquid crystalline di-, tri- and tetrafluorophenylpyrazines
INVENTOR(S): Brown, John William; Hurst, Derek Thomas; O'Donovan, Jaqueline Patricia; Coates, David; Greenfield, Simon; Goulding, Mark John; Gray, George William
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

PRIORITY APPLN. INFO.: JP 1993-176525 19930716
OTHER SOURCE(S): MARPAT 122:290892
GI

SOURCE: Brit. UK Pat. Appl., 22 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2272216	A1	19940511	GB 1992-23244	19921104
PRIORITY APPLN. INFO.:			GB 1992-23244	19921104

OTHER SOURCE(S): MARPAT 121:108837
GI



I



II

AB Phenylpyrazine derivs. [I; R1, R2 = (un)substituted alkyl or alkenyl; L1, L2 = H, F], useful as components of liquid-crystalline phases in liquid crystal display devices (no data), are prepd. Thus, (difluorophenyl)pyrazine II was prepared from PrCOMe in 4 steps.
IT 156573-06-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as liquid crystal)
RN 156573-06-7 CAPLUS
CN Pyrazine, 2-(2,3-difluoro-4-propoxyphenyl)-5-(pentyloxy)- (9CI) (CA INDEX NAME)



LS ANSWER 40 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:483377 CAPLUS
DOCUMENT NUMBER: 121:83377
TITLE: (Biphenylyl)pyrazines for liquid crystalline media
INVENTOR(S): Brown, John William; Hurst, Derek Thomas; O'Donovan, Jacqueline Patricia; Coates, David; Greenfield, Simon; Goulding, Mark John; Gray, George William
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: Brit. UK Pat. Appl., 40 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2271351	A1	19940413	GB 1992-21139	19921008
PRIORITY APPLN. INFO.:			GB 1992-21139	19921008

OTHER SOURCE(S): MARPAT 121:83377
GI



I



II

AB Biphenylylpyrazines I (R1, R2 = , haloalkyl, etc.; x = 0-2) were disclosed. Also claimed were [(cyclohexyl)phenyl]pyrazines. Liquid crystal media and electrooptical devices containing I are claimed. An example compound, 2-Pentyloxy-5-(4'-propyl[1,1'-biphenyl]-4-yl)pyrazine (II) was prepared
IT 156487-05-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as liquid crystal)
RN 156487-05-7 CAPLUS
CN Pyrazine, 2-(4-butoxy-2,3-difluorophenyl)-5-(pentyloxy)- (9CI) (CA INDEX NAME)



LS ANSWER 41 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:269942 CAPLUS
DOCUMENT NUMBER: 120:269942
TITLE: Preparation of Cypridinida's luciferin derivatives as luminescent probes for chemiluminescence immnoassay
INVENTOR(S): Sawada, Hideo; Totani, Yoshiaki; Mitani, Motohiro; Ichikawa, Hideji; Matsumoto, Takeo
PATENT ASSIGNEE(S): Nippon Oils & Fats Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05286976	A2	19931102	JP 1992-13167	19920128
JP 3314397	B2	20020812		
PRIORITY APPLN. INFO.:			JP 1992-13167	19920128

OTHER SOURCE(S): MARPAT 120:269942
GI



I



II

AB The title compds. (I; R1 = H, C1-4 alkyl, alkoxy; R2 = H, C1-10 alkyl, N-succinimidyl; n = 1-10) are prepared I react with biol. important substances such as antigens, antibodies, hormones, drugs, drug metabolites, toxins, and alkaloids to form luminescent compds. and thus are used as reagents for luminescent anal. and chemiluminescence immunoassay (no data). Thus, iso-Pr levulinate was oxidized by SeO2 in iso-PrOH at 80° to give 50% glyoxal derivative HCOCOCH2CH2CO2CHMe2 which was cyclocondensed with 2-amino-6-(p-methoxyphenyl)pyrazine in the presence of concentrated HCl in iso-PrOH at 70° to give a phenylimidazopyrazine derivative (II; R2 = iso-Pr). The latter compound was hydrolyzed in 3N HCl at 60° to give 60% II (R2 = H). Addnl. 9 I were prepared
IT 154616-04-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with glyoxal derivative)
RN 154616-04-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



LS ANSWER 42 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:245160 CAPLUS
DOCUMENT NUMBER: 120:245160
TITLE: Preparation of indolopyrazines and related compounds as brain GABAa agonists, antagonists, or inverse agonists
INVENTOR(S): Blum, Charles; Hutchison, Alan
PATENT ASSIGNEE(S): Neurogen Corp., USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5286860	A	19940215	US 1992-975409	19921112
WO 9411374	A1	19940526	WO 1993-US10870	19931110
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9455526	A1	19940608	AU 1994-55526	19931110
US 5606059	A	19970225	US 1995-436252	19950512
US 5668283	A	19970916	US 1995-486595	19950607
PRIORITY APPLN. INFO.:			US 1992-975409 A	19921112
			WO 1993-US10870 W	19931110
			US 1995-436252 A2	19950512

OTHER SOURCE(S): MARPAT 120:245160
GI For diagram(s), see printed CA Issue.
AB Title compds. [I; ring Q = Q1, Q2; n = 0-2; R1, R2 = H, alkyl; Y = various organic and inorg. substituents; W = aromatic group substituted with various organic and inorg. substituents; A = CH, N; B = (substituted) C, N; and E = H, alkyl]. These compds. are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine type drugs, and enhancement of alertness. Thus, glycinamide was cyclocondensed with 2-fluoro-5-methoxyphenyl glyoxal to give 5-(2-fluoro-5-methoxyphenyl)pyrazin-2-one. This was chlorinated with POCl3 followed by condensation with hydrazine to give 2-hydrazino-5-(2-fluoro-5-methoxyphenyl)pyrazine. The latter was condensed with cyclohexanone to give the hydrazone, which was refluxed in diethylene glycol to give title compound I. I showed IC50 = 0.200 μM for binding to GABAa receptors.
IT 154032-58-3P 154032-60-7P 154032-61-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for GABAa receptor ligand)
RN 154032-58-3 CAPLUS
CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 154032-60-7 CAPLUS
CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)-, hydrazone (9CI) (CA INDEX NAME)

CAS MISTAKE. REF. DOESN'T DISCLOSE

R1, R3 = H
J, K = C
G = O
Rx = ALKYL C5
R5 = HALO
R7 = ALKOXY
R8 = H

THIS REFERENCE, GB2271351, DOES NOT DISCLOSE THAT COMPOUND.

EX. 2 PG 30 IS WHAT THE CAS-INDEXED COMPOUND IS REFERRING TO. THERE IS AN INTERPOSED PHENYLENE RING IN THE REF. COMPD.

ERROR *REPORTED TO CAS 6/29/05



RN 154032-61-8 CAPLUS
CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)-, cyclohexylidenehydrazone (9CI) (CA INDEX NAME)



L5 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:571380 CAPLUS
DOCUMENT NUMBER: 117:171380
TITLE: Metalation of diazines. VI. Metalation of pivaloylaminopyrazine and N-tert-butylpyrazinamide. Unusual regioselectivity in the metalation reaction.
AUTHOR(S): Turck, A.; Ple, N.; Trohay, D.; Ndzi, B.; Queguiner, G.
CORPORATE SOURCE: Lab. Chim. Org. Fine Heterocyclique, INSA, Mt. St. Aignan, 76131, Fr.
SOURCE: Journal of Heterocyclic Chemistry (1992), 29(4), 699-702
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:171380
AB Metalation of (pivalamido)pyrazine and N-(t-butyl)pyrazinamide were studied. For (pivalamido)pyrazine the yields were poor and some addition products were isolated. The metalation of t-butylpyrazinamide was successful and a curious regioselectivity was highlighted.
IT 143769-10-2P, 3-Benzyl-2-(pivaloylamino)-5-mesitylpyrazine
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselective preparation of)
RN 143769-10-2 CAPLUS
CN Propanamide, 2,2-dimethyl-N-[3-(phenylmethyl)-5-(2,4,6-trimethylphenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



CN Pyrazinamine, 5-(2-chlorophenyl)-6-methyl- (9CI) (CA INDEX NAME)



IT 69816-72-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and insecticidal activity of)
RN 69816-72-4 CAPLUS
CN Benzamide, 2-chloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 69816-87-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 69816-87-1 CAPLUS
CN Benzamide, 2-chloro-N-[[[6-methyl-5-(2-methylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1980:620777 CAPLUS
DOCUMENT NUMBER: 93:220777
TITLE: Substituted 2-aminopyrazines
INVENTOR(S): Barnett, Charles J.; Emmick, Thomas L.; Hoying, Richard C.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

L5 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1982:35307 CAPLUS
DOCUMENT NUMBER: 96:35307
TITLE: 1-(Mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
INVENTOR(S): Miesel, John L.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 881,300, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4293552	A	19811006	US 1979-62393	19790731
PRIORITY APPLN. INFO.:			US 1978-881300	A2 19780227

GI



AB Aminopyrazines underwent an addition reaction with 2-RC6H4CONCO (R = Br, Cl) to yield the resp. ureas I [R1 = H, Cl, Me, CF3; R2 = H, CF3, Ph, halo-, methoxy-, (trifluoromethyl)-, or phenylphenyl], which exhibited insecticidal activity. Thus, 2-ClC6H4CONCO was added to 2-amino-5-(4-bromophenyl)-6-methylpyrazine and the mixture was stirred overnight to give I (R = Cl, R1 = Me, R2 = 4-BrC6H4).
IT 59489-79-1 69816-56-4 80348-73-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(addition reaction of, with chlorobenzoyl isocyanate)
RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 69816-56-4 CAPLUS
CN Pyrazinamine, 6-methyl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 80348-73-8 CAPLUS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4211870	A	19800708	US 1979-27630	19790406
DK 8001442	A	19801007	DK 1980-1442	19800402
FI 8001056	A	19801007	FI 1980-1056	19800402
AU 8057102	A1	19801009	AU 1980-57102	19800402
FR 2453159	A1	19801031	FR 1980-7457	19800402
BR 8002079	A	19801125	BR 1980-2079	19800402
ES 490287	A1	19810516	ES 1980-490287	19800402
CS 215055	P	19820730	CS 1980-2293	19800402
CA 1157860	A1	19831129	CA 1980-349061	19800402
BE 882608	A1	19801003	BE 1980-9771	19800403
EP 18144	A1	19801029	EP 1980-301085	19800403
R: DE, GB, NL, SE				
GB 2046751	A	19801119	GB 1980-11363	19800403
GB 2046751	A1	19801119		
DD 150057	C	19810812	DD 1980-220207	19800403
ZA 8002005	A	19811125	ZA 1980-2005	19800403
HU 26151	O	19830928	HU 1980-817	19800403
SU 932989	A3	19820530	SU 1980-2902455	19800404
RO 79384	P	19820625	RO 1980-100722	19800404
JP 55141473	A2	19801105	JP 1980-45114	19800405
PRIORITY APPLN. INFO.:			US 1979-27630	A 19790406

GI



AB 2-Amino-5-phenylpyrazines I [n = 0, 1, 2 (R = H, halo, alkyl, CF3); R1 = H, alkyl; R2 = alkyl] were prepared from the resp. α-halobenzyl ketoximes II (X = Cl, Br) and H2NCHR1CN (R1 same as above); H2NCHR1CN were treated with II and base to yield hydroxyimino-substituted aminoacetonitriles III, and the III were cyclized by polyphosphoric acid, H3PO4, or H3PO4-P2O5 at 50-140° to give I. Thus, H2NCH2CN.HCl was N-alkylated by 4-BrC6H4CHClC(:NOH)Me and Et3N, and the III (Rn = 4-Br, R2 = Me, R1 = H) product was heated with polyphosphoric acid to give I (Rn = 4-Br, R2 = Me, R1 = H).
IT 75411-09-5P 75411-10-8P 75411-11-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 75411-09-5 CAPLUS
CN Pyrazinamine, 5-(2-bromophenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 75411-10-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 75411-11-9 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[[5-(2,4-dimethylphenyl)-6-methylpyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1979:540598 CAPLUS
DOCUMENT NUMBER: 91:140598
TITLE: 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John L.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 19 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4160834	A	19790710	US 1977-861733	19771219
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
PRIORITY APPLN. INFO.:			US 1974-507492	A2 19740919
			US 1975-595904	A2 19750714
			US 1977-775813	A2 19770309
			AT 1975-7146	A 19750917

GI



I

AB Adding benzoyl isocyanates to aminopyrazines gave ureas I [R, R1 (same or different) = halo, Me, CF3; R2, R3 (same or different) = H, alkanoyl, alkoxycarbonyl; R4 = H, halo, alkyl, cycloalkyl, haloalkyl, NO2, cyano, naphthyl, (CH2)nC6H4Zm (n = 0, 1; Z = halo, haloalkyl, alkyl, alkoxy, alkylthio, alkylsulfonyl, NO2, cyano, Ph; m = 0, 1, 2, 3.), XC6H4Zm (X = O, S, SO2; Z and m as above); R5 = H, halo, Me, Et, cyano, haloalkyl], which were insecticidal. Thus, stirring 2-amino-5-chloropyrazine in cold EtOAc with 2,6-Cl2C6H3CONCO overnight gave I (R = R1 = R4 = Cl, R2 = R3 = R5 = H).
IT 59489-79-1 69816-56-4 71553-78-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(addition reaction of, with benzoyl isocyanate derivative)
RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 69816-56-4 CAPLUS
CN Pyrazinamine, 6-methyl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 71553-78-1 CAPLUS
CN Pyrazinamine, 5-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



IT 59489-64-4P 71544-77-9P 71544-80-4P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and insecticidal activity of)
RN 59489-64-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbony

l]- (9CI) (CA INDEX NAME)



RN 71544-77-9 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[[6-methyl-5-(2-methylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 71544-80-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[[5-(2-chlorophenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1979:152238 CAPLUS
DOCUMENT NUMBER: 90:152238
TITLE: 1-(Mono-o-substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John Louis; Abdulla, Riaz Fazal; Terando, Norman Henry
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Ger. Offen., 86 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2826893	A1	19790118	DE 1978-2826893	19780619
US 4133956	A	19790109	US 1977-819639	19770727
IL 54928	A1	19800228	IL 1978-54928	19780615
IL 64263	A1	19820930	IL 1978-64263	19780615
FR 2398738	A1	19790223	FR 1978-18187	19780616
FR 2398738	B1	19810508		
IN 149912	A	19820529	IN 1978-CA666	19780616
BE 868228	A1	19781219	BE 1978-8936	19780619
GB 2001053	A	19790124	GB 1978-27260	19780619
GB 2001053	B2	19820526		
AU 516505	B2	19810604	AU 1978-37249	19780619
AU 7837249	A1	19800103		
GB 2066806	A	19810715	GB 1980-19107	19780619
GB 2066806	B2	19820818		
AT 7804456	A	19811015	AT 1978-4456	19780619
AT 367046	B	19820525		
CA 1129861	A1	19820817	CA 1978-305703	19780619
HU 23227	O	19820830	HU 1978-EI793	19780620
HU 180726	B	19830429		
RO 78069	P	19820803	RO 1978-94410	19780620
HU 29287	O	19840130	HU 1982-1470	19780620
HU 185336	B	19850128		
DK 7802793	A	19781223	DK 1978-2793	19780621
SE 7807127	A	19781223	SE 1978-7127	19780621
NL 7806678	A	19781228	NL 1978-6678	19780621
BR 7803939	A	19790220	BR 1978-3939	19780621
ZA 7803553	A	19800227	ZA 1978-3553	19780621
CS 198104	P	19800530	CS 1978-4095	19780621
CS 198105	P	19800530	CS 1978-8519	19780621
CS 198106	P	19800530	CS 1978-8520	19780621
SU 799662	D	19810123	SU 1978-2628947	19780621
CH 638500	A	19830930	CH 1978-6770	19780621
JP 54009288	A2	19790124	JP 1978-76343	19780622
ES 471057	A1	19800116	ES 1978-471057	19780622
DD 141831	C	19800521	DD 1978-206203	19780622
DD 143721	C	19800910	DD 1978-213690	19780622
PL 115711	B1	19810430	PL 1978-207831	19780622
ES 471879	A1	19790201	ES 1978-471879	19780719
CA 1103251	A1	19810616	CA 1978-308083	19780725
FR 2398739	A1	19790223	FR 1978-32550	19781117
FR 2398739	B1	19821105		
IL 64216	A1	19821231	IL 1979-64216	19790615
AT 8101716	A	19820415	AT 1981-1716	19810415
DK 8103054	A	19810709	DK 1981-3054	19810709
SE 8303206	A	19830607	SE 1983-3206	19830607
PRIORITY APPLN. INFO.:			GB 1977-26093	A 19770622
			US 1977-819639	A 19770727
			IL 1978-54928	A3 19780615
			AT 1978-4456	A 19780619
			GB 1978-27260	A 19780619
			DK 1978-2793	A 19780621

GI



I

AB The insecticidal compds. I [R = halogen, Me, CF3; R1 = H, halogen, Me, CF3; R2 = H, C1-6 alkyl, haloalkyl, CN, (substituted) phenylalkyl, PhO, PhS; R3 = H, Me, CN, halogen, haloalkyl; R2R3 = CH:CHCH:CH; X, X1 = CH, N] were prepared Thus, 2-amino-5-(4-bromophenyl)-6-methylpyrazine reacted with

2-ClC6H4CONCO to give I (R = Cl, R1 = H, R2 = 4-BrC6H4, R3 = Me, X = X1 = N), which at 5 ppm gave 100% kill of Spodoptera eridania larvae.

IT 69816-72-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and insecticidal activity of)

RN 69816-72-4 CAPLUS
CN Benzamide, 2-chloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 69816-87-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 69816-87-1 CAPLUS
CN Benzamide, 2-chloro-N-[[[6-methyl-5-(2-methylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 59489-79-1 69816-56-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with benzoyl isocyanate)

RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 69816-56-4 CAPLUS
CN Pyrazinamine, 6-methyl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)



IT 59489-79-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dichlorobenzoyl isocyanate)

RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1970:50924 CAPLUS
DOCUMENT NUMBER: 88:50924
TITLE: 1-Benzoyl-3-pyrazinylureas
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52010285	A2	19770126	JP 1976-1426	19760101
PRIORITY APPLN. INFO.:			US 1975-595904 A	19750714

GI



I

AB I [R = H, Cl, Me, (substituted)Ph, etc.; R1 = H, Cl, Me, Et, CN, or RR1 = benzo; R2 = Cl, Me] were prepared by reaction of 2-amino-5-R-6-R1-pyrazoles (II) with benzoyl isocyanates 2,6-R22C6H3CONCO III. I are agricultural insecticides. Thus, 0.25 g II (R = Ph, R1 = H) and 0.45 g III (R2 = Cl) in AcOEt were stirred overnight to give the corresponding I.

IT 59489-79-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of, with benzoyl isocyanate, benzoylpyrazinylurea derivative from)

RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT 59489-64-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and insecticidal activity of)

RN 59489-64-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1976:421468 CAPLUS
DOCUMENT NUMBER: 85:21468
TITLE: 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John L.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Ger. Offen., 70 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2541116	A1	19760408	DE 1975-2541116	19750915
DE 2541116	C2	19850718		
IN 142286	A	19770618	IN 1975-CA1744	19750910
BE 833288	A1	19760311	BE 1975-1006877	19750911
IL 48092	A1	19790312	IL 1975-48092	19750912
AU 7584845	A1	19770324	AU 1975-84845	19750915
GB 1521714	A	19780816	GB 1975-37933	19750916
CA 1070308	A1	19800122	CA 1975-235561	19750916
NL 7510901	A	19760323	NL 1975-10901	19750917
ZA 7505945	A	19770427	ZA 1975-5945	19750917
AT 7507146	A	19771015	AT 1975-7146	19750917
CS 195710	P	19800229	CS 1975-6298	19750917
DK 7504195	A	19760320	DK 1975-4195	19750918
SE 7510474	A	19760322	SE 1975-10474	19750918
SE 426066	B	19821206		
SE 426066	C	19830317		



L5 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1970:509584 CAPLUS
DOCUMENT NUMBER: 89:109584
TITLE: Insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John Louis
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4003977	A	19780411	US 1976-742948	19761118
US 3984137	A	19761005	US 1975-595504	19750714
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
PRIORITY APPLN. INFO.:			US 1974-507492 A2	19740919
			US 1975-595504 A3	19750714
			AT 1975-7146 A	19750917

GI



I

AB The title compds. I (R = R1 = H, RR1 = unsubstituted, halo, C1-6 alkyl, C3-6 cycloalkyl NO2, CN, C1-4 haloalkyl-substituted benzo; R2, R3 = H, C1-4 alkanoyl, C1-3 alkoxycarbonyl; R4, R5 = halo, Me, F3C) were prepared Thus, 2-amino-5-chloropyrazine (II) was treated with 2,6-Cl2C6H4CONCO to give 3-(5-chloro-2-pyrazinyl)-1-(2,6-dichlorobenzoyl)urea (III). II was prepared by chlorination of Me 2-amino-3-pyrazinecarboxylate followed by hydrolysis and decarboxylation. At 50 ppm III completely controlled southern armyworm after 4 days.

IT 59489-64-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and insecticidal activity of)

RN 59489-64-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

PL 102954	P	19790531	PL 1975-197527		19750918
PL 106054	P	19791130	PL 1975-183470		19750918
CH 617192	A	19800514	CH 1975-12147		19750918
HU 19446	O	19810228	HU 1975-EI646		19750918
HU 177200	P	19810828			
JP 51056480	A2	19760518	JP 1975-114226		19750919
NL 7506073	A	19760803	NL 1975-6073		19750919
FR 2299327	A1	19760827	FR 1975-28772		19750919
FR 2299327	B1	19780407			
DD 123341	C	19761212	DD 1975-188451		19750919
ES 441124	A1	19770616	ES 1975-441124		19750919
DD 128762	C	19771207	DD 1975-196898		19750919
SU 662011	D	19790505	SU 1975-2171811		19750919
SU 660566	D	19790430	SU 1976-2380308		19760709
AT 7705635	A	19800615	AT 1977-5635		19770729
AT 360800	B	19810126			
SE 7806517	A	19780602	SE 1978-6517		19780602
SE 420042	B	19810914			
SE 420042	C	19820107			

PRIORITY APPLN. INFO.: US 1974-507492 A 19740919
AT 1975-7146 A 19750917

GI



I II

AB Insecticidal dichlorobenzoylureidopyrazines I [R = Cl, Ph, H, Me, Br, Et, substituted phenyl, CH2CMe3, CMe3; R1 = H, Me, Cl, CN; RR1 = substituted (CH)4] (29 compds.) were prepared by treating aminopyrazines II with 2,6-Cl2C6H3CONCO, obtained by treating 2,6-Cl2C6H3CONH2 with (COCl)2. At 1000 ppm I gave complete control of Spodoptera eridania.

IT 59489-64-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and insecticidal activity of)

RN 59489-64-4 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 59489-79-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dichlorobenzoyl isocyanate)

RN 59489-79-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1973:537092 CAPLUS
DOCUMENT NUMBER: 79:137092
TITLE: Pteridines. XXIX. Unequivocal route to 2,4-diamino-6-substituted pteridines
AUTHOR(S): Taylor, Edward C.; Perlman, Katherine L.; Kim, Young-Ho; Sword, Ian P.; Jacobi, Peter A.
CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, USA
SOURCE: Journal of the American Chemical Society (1973), 95(19), 6413-18
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB 2,4-Diamino-6-substituted pteridines (I) are prepared. Reaction of an α-keto-aldoxime with aminomalononitrile gives 2-amino-3-cyano-5-substituted pyrazine 1-oxides which yield 2,4-diamino-6-substituted pteridine 8-oxides upon cyclization with guanidine. 2,4-Diaminopteridines are then obtained by deoxygenation of the corresponding 8-oxides, or alternately by prior deoxygenation of these pyrazine 1-oxides, followed by cyclization with guanidine. The conversion of 2-amino-3-cyano-5-methylpyrazine 1-oxide to the corresponding 1,4-dioxide, and a number of chemical transformations of this latter intermediate, are also described.

IT 50627-21-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of, diaminopteridine from)

RN 50627-21-9 CAPLUS

CN Pyrazinecarbonitrile, 3-amino-6-(2-methoxyphenyl)-, 4-oxide (9CI) (CA INDEX NAME)



=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	240.23	402.63
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-27.01	-27.01

STN INTERNATIONAL LOGOFF AT 14:52:32 ON 29 JUN 2005